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Abstract 
Copy number variation (CNV) is a relatively novel source of genetic variation, involving the 
duplication or deletion of segments of genomic DNA (gDNA) sequence, thereby changing 
the original number of DNA copies. It is currently gaining widespread recognition from the 
scientific community, and it is anticipated to play a major role in the aetiology of human 
diseases.  However,  the  extent  of  its  contribution  to  phenotypic  diversity,  in  terms  of 
individual susceptibility to disease, remains to be elucidated. Nonetheless, recent studies 
have indicated that common complex disease phenotypes, such as osteoporosis, might be 
highly susceptible to CNV. 
Osteoporosis is a common and debilitating skeletal condition, imposing significant clinical 
and socioeconomic consequences. The disease is characterised by fragile bones that are 
susceptible to fracture due to deregulated bone remodelling, where bone loss exceeds bone 
formation. Being a common complex disease, osteoporosis risk is largely determined by the 
effect of environmental factors on genetic variants. Moreover, identification of the genetic 
variants associated with osteoporosis is widely anticipated for the contribution it will make 
towards the development of improved measures of disease intervention. 
Recent genome-wide association studies (GWASs) have identified that the genes oestrogen 
receptor 1 (ESR1) and Axin 1 (AXIN1) potentially play major roles in bone regulation. In 
addition,  evidence highlights  their  involvement  in  key  biological  processes  that  regulate 
bone turnover. Specifically, ESR1 mediates the response of bone marrow-derived cells to 
oestrogen and it has been demonstrated that oestrogen inhibits bone loss, while AXIN1 
inhibits Wnt signal transduction and it has been demonstrated that Wnt proteins promote 
bone  growth.  Furthermore,  several  large-scale  analysis  projects  firmly  implicate  genetic  
xiii 
 
variations  of  both  genes  with  bone  marrow  density  (BMD),  which  is  the  surrogate 
phenotype of osteoporosis. Therefore, ESR1 and AXIN1 are both recognised candidates for 
the genetic regulation of osteoporosis risk. 
This study investigated the potential effect of two novel CNVs of the genes ESR1 and AXIN1, 
Variant_4512 and Variant_4912, respectively, in relation to BMD in a population cohort 
study of Caucasian women, between the ages of 18 and 83, from Australia and the UK. 
Subjects  were  genotyped  for  both  CNVs,  respectively,  using  real-time  quantitative  PCR 
(qPCR) combined with TaqMan chemistry, and the copy number (CN) quantitation software, 
CopyCaller. Subjects were then examined for evidence of association between both CNVs 
and three different BMD phenotypes, 1) raw measurement (g/cm
2), 2) age-adjusted Z-score, 
and 3) controlled for several covariates, at three common skeletal locations of osteoporotic 
fracture, 1) lumbar spine, 2) total hip, and 3) femoral neck. 
This study confirmed the presence of ESR1 CNV and AXIN1 CNV in the analysed subject 
cohort,  as  indicated  by  the  observation  of  three  distinct  CNV  genotypes  for  each, 
representing CN loss (CN1) and CN gain (CN3) from the expected wild-type CN in the human 
diploid genome (CN2). This study found no evidence of association between both CNVs and 
BMD (p = > 0.05) in the analysed subject cohort. Therefore, the hypothesis tested in this 
study, that CNV is associated with BMD, was not supported. As a result, it would appear that 
the ESR1 CNV Variant_4512 and the AXIN1 CNV Variant_4912 are unlikely to play a major 
role in the pathogenesis of osteoporosis in Caucasian women. However, replication studies 
and further research would be required to accurately validate this, since this study was 
subject  to  numerous  limitations  which  may  have  influenced  the  findings,  such  as  low 
statistical power, technical difficulties, limiting experimental reagents, and time constraints.  
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In addition, there is evidence from previous studies implicating intron 1 and the 5’ end of 
ESR1 and intron 2 of AXIN1 with BMD. Variant_4512 and Variant_4912 encompass the 5’ 
end of their respective genes, thereby implicating the promoter sequence and regulatory 
elements, which in turn implicates the control of gene expression. Therefore, despite the 
lack of statistically significant findings in this study, the ESR1 CNV Variant_4512 and the 
AXIN1 CNV Variant_4912 both still remain as promising candidates for involvement in BMD 
and the risk of osteoporosis. Moreover, other CNVs in the same genomic regions may also 
be relevant for future research. 
Further research would benefit from addressing the potential effect of environmental risk 
factors  on  CNV.  It  is  possible  that  the  ESR1  CNV  Variant_4512  may  be  modified  in  an 
environment-specific  manner,  which  influences  its  effect  on  BMD,  as  indicated  by  the 
almost  statistically  significant  association between  ESR1  CNV  and  BMD  observed  in this 
study when controlled for covariates at the femoral neck (p = 0.052). Moreover, previous 
studies highlight that the majority of known genes subject to CNV are not even located 
within the identified region of genomic variation, and also that osteoporosis may be more 
susceptible to genetic variation affecting the CN of non-coding regions. Therefore, further 
research should also focus on gene expression studies to determine whether the ESR1 CNV 
Variant_4512 exerts position effects on the transcriptional control of another gene, which 
may in turn be the primary gene associated with osteoporosis. 
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Chapter 1: Introduction 
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1.1 The Impact of Osteoporosis 
Osteoporosis is a serious form of musculoskeletal disease [1] and it is the most prevalent 
metabolic  bone  disorder  [2].  It  is  currently  estimated to  affect  over  200  million people 
worldwide [3], with postmenopausal women and the elderly of Caucasian descent among 
those at the highest risk [4]. The disease is characterised by a gradual, systemic reduction in 
the density and structural quality of bones [5], resulting in weakened, fragile bones that are 
easily susceptible to fracture [6]. Osteoporotic fractures can occur from minimal trauma, 
such as bending, lifting, or even coughing [7], but their incidence is mainly determined by 
the frequency and direction of falls [5]. Accordingly, the most common skeletal sites for 
osteoporotic fracture are usually where the most impact of a fall is endured, such as the 
lumbar spine, hip, pelvis, distal forearm and wrist [4]. 
Based on the 2007-08 National Health Survey (NHS) conducted by the Australian Bureau of 
Statistics (ABS), 620,000 Australians (3.2% of the total population) have doctor-diagnosed 
osteoporosis and it occurs mainly in people aged 55 years and over (84.0%), with women 
accounting for more than eight out of ten cases (81.9%) [4]. The high incidence of the 
disease among women and the elderly may be consistent with trends reported worldwide, 
but the prevalence of doctor-diagnosed osteoporosis is most certainly underestimated [4]. 
The disease lacks overt symptoms and most cases are, therefore, likely to go undiagnosed 
[4]. People with osteoporosis are usually unaware that they even have the disease until a 
minor  trauma  results  in  a  fracture  and  subsequent  radiographs  demonstrate  the 
characteristic low bone mass and poor bone quality of osteoporosis [8]. According to the 
Osteoporosis Australia research group, a more accurate estimate of the actual number of 
people in Australia with the disease is 2.2 million (9% of the total population) [9]. The group  
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also estimates that an osteoporotic fracture occurs every 5-6 minutes in Australia and their 
incidence is predicted to rise to every 3-4 minutes by 2021 [9]. 
Osteoporosis  is  aptly  referred  to  as  ‘the  silent  disease’  [10],  considering  that  it  fails  to 
demonstrate overt physiological effects until it ultimately manifests itself as a fracture [8]. 
Osteoporotic  fractures  are  a  source  of  severe  pain,  immobility  and  disability  [10].  They 
cause gradual physical alterations, including loss of height and changes in posture [11], such 
as the development of a stooped back (i.e. Dowager’s hump) [9]. Moreover, they can have 
psychological effects, such as depression due to chronic pain or loss of independence [11]. 
Furthermore, clinical research highlights an increased risk of premature mortality with the 
disease, which is related to possible co-morbidities such as rheumatism and stroke [12]. 
Therefore, the quality of life for people affected by osteoporosis is expected to become 
progressively worse as the number and severity of fractures increases. It is estimated that 
50% of people with one fracture due to osteoporosis will have another. Therefore, the risk 
of  future  fractures  increases  exponentially  with  each  new  fracture.  This  trend  is  aptly 
referred to as the ‘fracture cascade effect’ [9]. According to Osteoporosis Australia, people 
who have had two or more osteoporotic fractures are up to 9 times more likely to have 
another fracture, rising to an 11 times greater risk for people who have had three or more 
fractures, compared to someone who has not had one [9]. 
The ‘fracture cascade effect’ constitutes a major socioeconomic concern that will place a 
substantial  burden  on  health  services  as  the  population  ages  and  the  number  of 
osteoporotic fractures increases [9]. Based on statistical evidence compiled for Australia in 
2007  by  the  Access  Economics  consultancy  group,  osteoporosis  has  a  total  health 
expenditure that exceeds $7 billion per year, with $1.9 billion spent on direct costs, such as  
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pharmaceutical medications and surgical procedures, and a further $5.6 billion spent on 
indirect costs, such as financial assistance for lost employment and earnings [13]. These 
figures are comparable with the prevalence and expenditure of osteoporosis worldwide 
[13]. Therefore, the impact of osteoporosis on sufferers, coupled with the socioeconomic 
burden of the disease, deserves attention. The value of disease intervention, in the form of 
prevention, diagnosis and treatment, highlights the importance of current research efforts 
to better comprehend the pathogenesis of osteoporosis and how it deviates from normal 
bone biology. 
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1.2 The Osteoporotic Disease Process 
As previously stated, osteoporosis is a systemic bone disease, characterised by increased 
fragility of bones, lacking overt symptoms until it clinically manifests itself in the form of 
fracture. The three main pathological mechanisms by which skeletal fragility can develop 
are as follows; firstly, failure to produce a skeleton of optimal mass and strength during 
growth;  secondly,  excessive  bone  loss,  resulting  in  decreased  bone  mass  and  structural 
deterioration of bone tissue micro-architecture; and thirdly, an inadequate bone formation 
response [5]. The interplay between these three mechanisms is what ultimately underlies 
the  development  of fragile  bones  in the  osteoporotic  disease process  [5].  Although the 
relative  contribution  of  each  remains  unclear  [5],  clinical  studies  demonstrate  that  the 
underlying cause of these three mechanisms, and hence the potential underlying cause of 
osteoporosis,  is  an  imbalance  in  the  bone  remodelling  process  at  the  cellular  level  [5], 
where bone resorption by osteoclasts exceeds bone formation by osteoblasts [6].  
1.2.1 Bone Biology 
1.2.1.1 Bone Remodelling 
Bone remodelling is a normal, lifelong process by which mature bone tissue is resorbed, or 
removed from the skeleton, and new bone tissue is deposited [6]. The skeletal system is 
constantly subject to turnover throughout life, with up to 10% of existing bone in a healthy 
human skeleton replaced every year [6]. In brief, bone is formed from a combination of 
dense compact bone and cancellous bone that is re-enforced at specific points of stress [14]. 
It is also comprised of blood and lymphatic vessels, nerve fibres, collagen and cells [14]. 
Furthermore, there are three main cell types found in bone, which are crucial in the bone  
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remodelling  process;  osteoclasts  (resorb  bone),  osteoblasts  (form  bone)  and  osteocytes 
(differentiated  osteoblasts  that  mediate  the  activity  of  osteoclasts  and  osteoblasts)  [6]. 
Bone  is  a  dynamic  connective  tissue,  which  is  highly  specialised  for  its  numerous 
physiological  functions,  including  protection,  support,  mechanical  load-bearing  and  the 
maintenance  of  mineral  homeostasis  and  haematopoiesis  [15].  Therefore,  maintaining 
healthy  bone  tissue  is  essential  for  regulating  normal  physiological  activity.  The  most 
dynamic function of bone lies with its capacity to remodel itself in response to metabolic 
and structural demands, which is fundamental for maintenance of skeletal integrity and 
healthy ageing [16].  
The  three  main  purposes  of  bone  remodelling  are  as  follows;  firstly,  it  repairs 
microfractures, or perforations in bone tissue that occur during normal daily activity [17]; 
secondly, it allows the skeletal system to act as a reservoir for minerals that are vital to 
physiological processes such as conduction of nerve impulses and muscle contraction [17]; 
and thirdly, it regulates bone mass at the cellular level [17]. Furthermore, the activities of 
bone remodelling’s two sub-processes, bone resorption by osteoclasts and bone formation 
by osteoblasts, are tightly coupled, and bone mass will remain stable as long as the amount 
of bone removed is evenly balanced by the amount of new bone deposited [16]. 
1.2.1.2 Bone Regulation 
There are several known molecular regulators that determine the rate of bone turnover. 
Firstly,  it  is  well  documented  that  circulating  hormones  control  the  balance  of  bone 
remodelling [5]. For example, increased levels of oestrogen, calcium, and vitamin D, and 
decreased levels of PTH, not only increase the deposition of new bone, but also decrease 
bone  resorption  [5].  Secondly,  bone  resorption  is  primarily  regulated  by  the  
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RANK/RANKL/OPG  pathway,  which  plays  a  central  role  in  osteoclast  differentiation  and 
function [18; 19]. The receptor activator of nuclear factor κB ligand (RANKL) is a molecular 
signal produced by osteoblasts and other cell types such as lymphocytes [18]. RANKL binds 
to  and  activates  RANK,  which  is  expressed  on  cells  of  the  osteoclast  lineage,  thereby 
activating  osteoclasts  and  promoting  bone  resorption  [18].  The  activity  of  RANKL  is 
regulated by the protein osteoprotegerin (OPG), which competes with RANK for binding to 
RANKL, and hence suppresses its ability to increase bone resorption [18; 19]. Thirdly, the 
Wnt signalling pathway is a recognised, albeit less understood, regulator of bone formation 
[19]. Members of the Wnt family of proteins bind to and activate the lipoprotein receptor-
related protein 5 encoded by the gene LRP5 [19]. There are at least 19 Wnt family members, 
and  it  remains  to  be  determined  which  are  the  most  important  in  regulating  bone 
metabolism, but current evidence suggests that Wnt7b and Wnt10b are both involved [19]. 
A variety of inhibitors of Wnt signalling have also been identified, including soluble frizzled-
related (Fz) proteins and sclerostin (SOST), and it is likely that regulation of bone formation 
depends on the balance between levels of stimulatory Wnt molecules and these inhibitors 
[19]. 
Therefore, the key regulators of bone remodelling constitute a finely-tuned process which 
relies on complex interactions among multifaceted signalling pathways and multiple local 
and systemic regulators of bone cell function to ultimately achieve proper rates of growth, 
differentiation  and  turnover.  Moreover,  clinical  studies  have  demonstrated  how  the 
disruption  of  key  bone  regulators  can  uncouple  the  activity  between  osteoclasts  and 
osteoblasts and lead to aberrant changes in bone mass. For example, overproduction of 
RANKL  has  been  implicated  in  a  variety  of  degenerative  bone  diseases  (i.e.  rheumatoid  
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arthritis)  [20]  and  Wnt  signalling  pathway  mutations  have  been  associated  with 
osteoporosis [19]. In view of this, when an imbalance in bone remodelling is biased towards 
bone resorption, bone tissue is expected to lose minerals much faster than the body can 
replace them, resulting in the reduced bone mineral density (BMD) that is characteristic of 
osteoporosis. 
1.2.2 Primary Risk Factors for Osteoporosis 
Osteoporosis may be most prevalent among elderly women of Caucasian descent, but the 
disease has the capacity to affect both women and men from all ethnic groups [4], provided 
that they are susceptible to specific risk factors. Although a combination of risk factors, 
including environmental, age-related, hormonal, dietary, medical, and lifestyle factors, have 
been implicated with osteoporosis, the relative contribution of each largely depends on the 
form  and  type  of  the  disease  [21].  Osteoporosis  can  be  broadly  categorised  as  either 
primary or secondary. Primary osteoporosis is due to ageing, so it mainly affects the elderly 
[22],  while  secondary  osteoporosis  develops  as  a  consequence  of  physiological  and 
pathological effects on the skeleton, resulting from disorders of other organs and tissues, 
which can affect people of any age [23]. Primary osteoporosis is the most common form of 
the  disease  and  can  be  further  divided  into  two  distinct  types  based  on  the  pathology 
observed [22]. Type I or postmenopausal osteoporosis is associated with the decrease in 
oestrogen levels experienced during menopause [5]. Oestrogen is essential for healthy bone 
regulation and primarily acts by preventing the activation of enzymes that initiate apoptosis 
of  bone-forming  osteoblasts  [5].  In  view  of  this,  any  event  associated  with  oestrogen 
deficiency is expected to be a primary risk factor for osteoporosis in women, such as the 
surgical  removal  of  ovaries  and  anorexia  nervosa  [24].  Type  II  or  senile  osteoporosis  is  
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prevalent in women and men, usually aged 70 years and over [23]. Age-related bone loss is 
far more complex and multifaceted compared to postmenopausal bone loss and involves a 
combination of multiple pathological factors that are already associated with old age, such 
as hormonal alterations and cellular changes [25]. The most obvious consequence of age-
related bone loss is the increased risk of fracture due to the frailty and propensity for falls 
associated with old age. Therefore, the primary risk factors for developing osteoporosis (i.e. 
being  a  postmenopausal  Caucasian  woman  over  55  years  of  age)  are  stable  and 
unpreventable. However, there are a number of contributing risk factors which can in fact 
be modified early in life to dramatically reduce the likelihood of developing the disease [26]. 
Therefore, the value of early intervention underscores the importance of current research 
effort to better detect and treat risk factors contributing to osteoporosis. 
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1.3 Early Intervention of Osteoporosis 
1.3.1 Detection of Fracture Risk via BMD 
As  previously  stated,  osteoporosis  is  ‘the  silent  disease’,  which  lacks  overt physiological 
symptoms until a fracture occurs and subsequent radiographs demonstrate the reduced 
bone mass and quality, which are characteristic of the disease. Therefore, the clinical and 
sociological  impact  of  osteoporosis  ultimately  lies  with  the  incidence  of  fractures  [19]. 
Fracture risk has been shown to increase exponentially with a decrease in BMD [22]. As 
previously stated, BMD is the most importance consequence of the biased bone remodelling 
process underlying osteoporosis. In view of this, low BMD is currently the best predictor of 
fracture risk; and accordingly, BMD is typically used as a surrogate phenotype for fracture 
risk and bone strength, and hence for osteoporosis itself [28]. BMD is a quantitative trait, 
which  can  be  measured  on  a  continuous  scale  [29],  thereby  underscoring  the  genetic 
contribution to osteoporosis. 
The measurement of BMD can be used to accurately diagnose low BMD before a fracture 
even occurs, therefore predicting the risk of future fractures [30]. A BMD test essentially 
determines how rich bones are in minerals such as calcium and phosphorus [9]. The higher 
the mineral content, the denser and stronger the bones are, and the less likely they are to 
fracture easily [9]. There are several different types of BMD tests, which can measure BMD 
at  various  skeletal  sites,  but  usually  focus  on  the  bones  most  likely  to  fracture  due  to 
osteoporosis  (i.e.  the  posterior-anterior  lumbar  spine  and  the  proximal  femur)  [31]. 
Currently, the standard BMD measurement technology is Dual energy X-ray Absorptiometry 
(DXA), because it is the most accurate and uses the least amount of radiation [31]. In brief,  
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DXA is based on the detection of uneven soft tissue composition by the emission of photons 
at two different energies [30]. 
The BMD test is then interpreted by using the BMD measurement (expressed in g/cm
2) to 
generate a personalised T-score and Z-score. A BMD T-score indicates how dense the bone 
is compared to what would be expected in a young healthy adult of the same gender as the 
subject [32]. The T-score is the number of standard deviations that the BMD is either above 
or below the young average population mean [32]. The more negative the BMD T-score, the 
thinner the bones are and thus the more likely they are to fracture easily [32]. Furthermore, 
a T-score above -1 is considered normal; between -1 and 2.5 is considered osteopenia (low 
bone mass); and, -2.5 or a more negative score is clinically defined as osteoporosis [32]. 
A BMD Z-score indicates how dense the bone is compared to what would be expected in a 
healthy adult of the same age, gender and ethnicity as the subject [32]. The Z-score is the 
number  of  standard  deviations  that  the  BMD  is  either  above  or  below  the  average 
population mean [32]. Ideally, a BMD Z-score should be between -2 and +2 [32]. A BMD Z-
score  more  negative  than  -2.5  indicates  that  bone  loss  is  lower  than  what  would  be 
expected  for  someone  of  the  same  age  [32].  Therefore,  it  indicates  that  bone  loss  is 
occurring for a reason unrelated to age, so further investigation would be required. 
1.3.2 Prevention of Osteoporosis 
As  previously  stated,  the  primary  risk  factors  for  osteoporosis  (i.e.  age,  gender,  and 
ethnicity)  may  be  unpreventable,  but  the  contributing  factors  (i.e.  low  BMD  and  high 
fracture risk) can be modified early in life to dramatically reduce the likelihood of developing 
the disease [26]. Existing measures to prevent osteoporosis focus primarily on building up  
12 
 
bone mass, as the more bone mass a person has at the age of peak bone mass, the more 
that can be lost without risk of osteoporosis [33]. Moreover, bone mass can be built up 
easily through healthy dietary and lifestyle habits between the ages of 25 and 40 [34]. For 
example, an adequate intake of calcium and vitamin D [35], along with regular moderate 
exercise  to  improve  weight-bearing  and  strength  [36],  are  known  to  be  important  for 
preventing osteoporosis. 
There are also prevention measures available for people who have already been diagnosed 
with osteoporosis, which aim to limit the severity and progression of the disease [37]. There 
are  a  number  of  drugs  available  for  the  prevention  of  bone  resorption.  For  example, 
bisphosphonates possess anti-osteoclastic activity [38]. It must be emphasized that drug 
treatments cannot cure osteoporosis; they aim to reduce further bone loss and fracture risk 
[4], but must be taken regularly and correctly to maintain their effects [10], which in some 
cases  may  be  minimal. Clinical  studies  have  demonstrated  that  drug  treatments  reduce 
fracture  risk  by  60%,  at  most  [39].  Therefore,  the  value  of  more  effective  intervention 
measures highlights the importance of current research efforts to elucidate the molecular 
markers of osteoporosis. 
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1.4 The Genetic Contribution to Osteoporosis 
As previously stated, there are many environmental factors, of modifiable sources (i.e. diet, 
physical activity, and drug use) and non-modifiable sources (i.e. age, gender, and ethnicity), 
which can influence the risk of osteoporosis. However, studies have shown that one of the 
most important clinical risk factors for phenotypes related to osteoporosis (i.e. BMD, bone 
mass and fracture risk) is a positive family history [19; 40], thereby underscoring the role of 
genetics in the aetiology of the disease. 
1.4.1 Common Complex Pattern of Inheritance 
Like obesity, diabetes, and neurological disorders, osteoporosis is a classic example of a 
common,  yet  complex  disease  [41].  These  diseases  involve  complex  interactions  among 
multiple risk factors of both genetic and environmental sources [42]. Although the relative 
contributions  of  both  sources  remain  to  be  fully  resolved,  studies  have  indicated  that 
multiple genetic variants are involved, with each having only a modest effect on common 
complex disease risk [43]. This is aptly referred to as the common disease/common variant 
hypothesis, which proposes that common disease-causing genetic variants exist in all human 
populations and each has a small, additive effect on the overall disease phenotype [44]. 
Although they may be similar to common monogenic/Mendelian conditions in that they 
strongly cluster in families and are highly heritable [43], the underlying genetic contribution 
of common complex conditions is inherently different. They do not demonstrate a simple 
pattern of inheritance according to Mendel’s Laws [45]. Instead, genetic factors represent 
only  part  of  the  associated  common  complex  disease  risk  [46].  Although  a  person  can 
harbour a genetic risk factor associated with a particular common complex disease, this 
does  not  necessarily  indicate  that  they  are  destined  to  develop  the  disease  [46].  
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Furthermore,  the  actual  common  complex  disease  phenotype  largely  depends  on  the 
interplay between both genetic and environmental risk factors [47]. 
In  view  of  this,  the  genetic  contribution  to  osteoporosis  can  be  easily  explained  by  a 
common, yet complex pattern of inheritance, considering that environmental factors have a 
strong  influence  on  the  risk  of  disease  [48].  Postmenopausal  osteoporosis  is  a  perfect 
example of how genetic factors can be modified in an environment-specific way to influence 
disease risk. Through interaction with oestrogen, the normal expression of the oestrogen 
receptor 1 gene (ESR1) promotes healthy bone turnover [19]. Therefore, the activity of ESR1 
can be modified by altered levels of oestrogen. For example, a decline in oestrogen levels is 
expected to imbalance the regulation of bone turnover, thereby increasing the susceptibility 
to phenotypes related to osteoporosis, such as low BMD. Consistent with this, an increase in 
oestrogen levels through hormone replacement therapy has been shown to decrease the 
risk of osteoporosis [49]. Therefore, rather than identifying the genetic and environmental 
components of osteoporosis separately, researchers tend to assess how they interact with 
one another [47]. This facilitates the detection of genetic factors that can be modified in an 
environment-specific way [46], which may in turn highlight effective targets for therapeutic 
intervention. 
1.4.2 Identification of Genetic Factors that are Associated with Disease  
There are a number of key mechanisms used for the study of osteoporosis. Until recently, 
the main strategies that were employed for the detection of common genetic variants and 
their association to complex diseases were positional cloning through genome-wide linkage 
scans [43] and candidate gene studies [50], respectively. Only a small number of disease 
genes have been recognised through these approaches, given their poor statistical power  
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and unreliable reproducibility [43]. Nonetheless, there have been successes in identifying 
candidate genes associated with the risk of osteoporosis, that continue to be implicated in 
the regulation of bone phenotypes (i.e. bone turnover, bone mass, BMD, and fracture risk) 
and include reproductive hormones, calcitrophic hormones, collagen genes, growth factors, 
and cytokines, and their corresponding receptors [51]. 
Association  analyses  generally  require  sophisticated  statistical  designs  incorporating  all 
genetic  and  non-genetic  variations,  their  interactions  and  familial  corrections  [52].  The 
recent acceleration in the pace of identifying and validating common genetic variants that 
enhance individual susceptibility to complex diseases can be attributed to the advent of 
high-throughput, large-scale genome-wide association studies (GWASs), which can identify 
disease-associated genes, even when there is no prior biological support for their role in 
that particular disease [53]. A GWAS can accurately determine the frequency of a genetic 
variant in a case-control study by scanning the entire genome of a person known to be 
affected  and  then  comparing  the  data  to  the  genome  of  an  unaffected  person  [54]. 
Furthermore, it is through such analyses that insights into the pathological processes that 
influence individual susceptibility to disease can be gained [55]. Accordingly, GWASs have 
had  successes  in  identifying  hundreds  of  loci  relevant  to  a  range  of  common  complex 
diseases  and  related  phenotypes  [56].  Although  most  studies  have  only  been  able  to 
account for, at most, 10% of the phenotypic variance among people [19], this is somewhat 
expected of a common complex disease phenotype. As previously stated, the phenotype 
depends on multiple genetic variants, with each having only a small additive effect overall, 
and their multifaceted interplay with environmental factors.  
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1.4.3 Evidence Supporting the Heritability of Osteoporosis 
There are several lines of evidence supporting the contribution of genetic factors towards 
phenotypes related to osteoporosis. Twin and family studies have shown that between 50 
and 85% of the variance in peak BMD among people is genetically determined [19]. This 
finding  highlights  the  potentially  strong  heritability  underlying  osteoporosis,  considering 
that BMD is the best known predictor of the disease [28]. Studies have shown that the 
heritability of BMD is usually highest at the most common fracture sites, such as the spine 
and hip [19]. In addition to BMD, heritability studies have also shown evidence of a strong 
genetic contribution to other determinants of fracture risk, such as BMI, muscle strength, 
quantitative  ultra-sound  properties  of  bone,  femoral  neck  geometry,  and  biochemical 
markers  of  bone  turnover  [19].  For  example,  a  study  of  biochemical  markers  that  was 
conducted by Hunter  et al in 2001 reported that the heritability of circulating levels of 
vitamin D and PTH was 60 and 65%, respectively [19].  
Although the key determinants of fracture risk have shown a strong genetic contribution, 
the  heritability  of  fracture  on  its  own  has  proved  more  difficult  to  demonstrate  [57]. 
Conflicting results have been reported, but most studies have estimated the heritability of 
fracture to be less than 50% [57]. This may be due to the complexity of the phenotype 
considering the multiple risk factors,  of both skeletal and non-skeletal sources, and the 
associated difficulty in collecting sufficiently powered data sets [19]. However, divergent 
results  and  weak  heritability  estimations  are  most  likely  explained  by  the  fact  that  the 
heritability  of  fracture  has  been  shown  to  decrease  with  age  as  environmental  factors 
become more important [19], such as impaired cognition and neuromuscular control, which 
can influence the propensity to fall.  
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There is promising evidence for a genetic contribution to bone characteristics relevant to 
osteoporosis. However, the underlying genetic basis of the disease, and the extent of this 
contribution relative to other risk factors, remains to be fully resolved. Therefore, continued 
research efforts are aimed at elucidating the genetic variations that determine individual 
susceptibility to osteoporosis. 
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1.5 Human Genetic Variation 
As previously stated, osteoporosis is a classic example of a common, yet complex disease, 
where the underlying genetic contribution depends on multiple genetic variations, which 
each have a small additive effect on the overall phenotype. The advent of high-throughput 
sequencing technologies has made it possible for researchers to generate a near-complete 
landscape  of  the  human  genome  [58].  Moreover,  recent  achievements  in  biomedical 
research, such as the Human Genome Project [58], the International HapMap Project [59], 
and  continuing  advancements  in  genomics,  bioinformatics,  research  methodologies  and 
high-throughput sequencing technologies [60], have revealed the abundance of variability 
that actually exists within the human genome sequence [58].  
Human genetic variation refers to differences, not just among cell types within a person 
[61],  but  also  between  people  [58].  Although  humans  have  been  reported  to  share 
approximately  99.9%  of  their  genome  sequence  [62],  evidence  suggests  that  no  two 
individuals are completely identical, and even monozygotic twins who develop from one 
zygote  have  demonstrated  infrequent  genetic  differences  [63].  Numerous  studies  have 
provided examples of evolutionary processes, such as selection, adaptation and genetic drift 
as  contributing  to  human  genetic  variation;  however,  the  relative  importance  of  each 
remains unclear [64]. Genetic differences have traditionally been thought to arise during 
intrauterine  development  [63]  as  a  consequence  of  various  mutational  events  in  DNA 
replication and meiosis [65]. However, it has been proposed that the mutation rate at most 
genomic positions is relatively low compared to that of the most recent ancestor of any two 
people [65]. Therefore, although they can arise from de novo mutations, it is reasonable to 
assume that the vast majority of genetic differences may be inherited [65]. In view of this,  
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genetic variation is a powerful resource for current research efforts towards elucidating how 
the  inherited  genetic  makeup  of  an  individual  can  influence  the  variable  expression  of 
particular traits; or put simply, how genotype affects phenotype. Through the analysis of 
variable  genomic  regions,  important  insights  have  been  gained  into  the  pathological 
processes which influence individual susceptibility to disease [55]. 
1.5.1 Functional Consequence of Human Genetic Variation 
Understanding how a DNA sequence exerts a functional effect is crucial towards elucidating 
phenotypic diversity [66]. Gene expression represents the most fundamental level at which 
the genotype gives rise to the phenotype [67] and virtually all aspects of cellular function 
rely on it being properly regulated [68]. Studies have validated that gene expression levels 
are  indeed  predictive  of  phenotypic  traits  globally,  as  demonstrated  by  genome-wide 
expression  profiling  studies,  and  also  on  an  individual  gene  basis,  as  demonstrated  by 
studies  connecting  regulatory  genetic  variation  in  adaptively  important  traits  [69]. 
Therefore,  the phenotypic  effects of  genetic  variation  are  most  likely  brought  about  by 
changes in gene expression levels [55]. Moreover, disruption of the underlying functional 
elements that regulate gene expression may largely determine individual susceptibility to 
disease [67].  
1.5.1.1 Transcriptional Control of Gene Expression 
Researchers  have  had  much  success  in  identifying  the  cellular  mechanisms  which  are 
involved in the control of gene expression [70]. It is generally accepted that transcriptional 
control is the main level at which the regulation of gene expression takes place [68]. The 
simplest model of transcriptional control involves the binding of transcription factors (TFs),  
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in  a  sequence-specific  manner,  to  TF  binding  sites  located  in  promoter  sequences  [70], 
which controls the flow of genetic information from DNA to mRNA [68]. Transcriptional 
control itself is influenced by a variety of mechanisms [71]. Evidence suggests that the two 
major points of transcriptional control are (i) through the modification of the chromatin 
structure  of  the  gene  locus,  and  (ii)  through  the  action  of  TFs;  however,  their  relative 
contributions remain unclear [71]. Although they are often described as separate events, 
these  two  processes  are  inherently  linked,  with  chromatin  structure  influencing  the 
accessibility of DNA to TFs, and the binding of TFs to DNA triggering chromatin modifications 
[72]. TFs can act alone or in a complex with regulatory elements [73]. For example, through 
interaction  with  the  promoter  sequence,  TFs  bound  to  an  enhancer  or  repressor  can 
mediate  positive  or  negative  control  of  the  rate  of  transcription,  respectively  [74]. 
Furthermore,  most  regulatory  elements  are  defined  as  position-  and  orientation-
independent  [74],  and  thus  may  be  ‘cis’-acting  or  ‘trans’-acting  –  that  is,  they  can  be 
proximal to the promoter  of  their target  gene [71]  or distal  and  thus active  over  large 
genomic distances [73], respectively. The majority of regulatory effects have been described 
as ‘cis’ [61], but a number of ‘trans’ effects have also been described [73]. 
Distal elements communicate regulatory activity over large spans of intervening DNA [73]. 
The model which is most commonly encountered in the context of long-range interactions is 
the  ‘looping’  mechanisms,  whereby  transcription  factors  bound  to  regulatory  elements 
make direct contact with the promoter sequence while the intervening DNA ‘loops out’ [73]. 
Therefore, it can be expected that interactions between the promoter and its regulatory 
elements can be disrupted through mutation or physical dissociation [71] at overlapping, 
nearby, or even long-range distances outside the transcription unit [70]. In some cases, the  
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expression level of a gene can be deleteriously affected by an alteration in its chromosomal 
environment,  while  maintaining  an  intact  transcription  unit  [62].  This  is  defined  as  a 
‘position effect’, where the disruption of normal transcriptional control is expected [71]. It is 
often less recognised that, in addition to the integrity of protein-coding sequences, human 
health  also  critically  depends  on  the  spatially,  temporally  and  quantitatively  correct 
expression  of  those  genes,  and disease  can  equally  be  caused  by  the  disruption  of the 
mechanisms which ensure proper gene expression [71]. Moreover, evidence shows that 
when the regulatory system of a gene is disrupted, expression can be adversely affected, 
and in some cases, can lead to disease [71].  
Therefore, understanding how genetic variation can encompass regulatory regions within 
the human genome and subsequently exert a functional consequence is crucial towards 
elucidating phenotypic diversity. 
1.5.2 Characterisation of Human Genetic Variation 
Due  to  growing  evidence  that  human  genetic  variation  may  play  an  important  role  in 
influencing  individual  susceptibility  to  common  complex  diseases,  such  as  osteoporosis, 
there have been considerable research efforts to categorise the genetic differences among 
people  [75].  The  near-completeness  of  the  human  genome  sequence  has  enabled  the 
accurate  characterisation  and  assessment  of  all  types  of  human  genetic  variation  [62]. 
Differences  in  the  genetic  code  are  usually  defined  in  terms  of  their  frequency  and 
nucleotide composition [56]. Despite common differences being more readily studied [43], 
genetic variation can be either common or rare, denoting the minor allele frequency (MAF) 
in a given population [56]. Common genetic variants are synonymous with ‘polymorphisms’ 
and are therefore defined as having a MAF greater than 1%, while rare genetic variants have  
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a MAF less than 1% [56]. DNA changes can be further divided into two broad classes based 
on their nucleotide composition; single nucleotide and structural [56]. 
1.5.2.1 Single Nucleotide Polymorphisms (SNPs) 
SNPs are the most prevalent source of genetic variation, with over 11 million reported to 
date [56]. They most often result from a non-repaired error during DNA replication [65] 
every 100 to 300 bases along the genome [56], in which one of the four possible nucleotides 
is substituted for another [76]. The term ‘polymorphism’ already denotes that they are 
common, with an estimated 7 million SNPs occurring in over 5% of a given population, and 
the remaining between 1 and 5% [56]. Studies have shown that the vast majority of SNPs 
are neutral; that is, they do not contribute to any specific cellular function and achieve 
significant frequencies simply by chance [77]. However, depending on their location within 
the genome, SNPs can alter sequence-specific cellular processes, such as gene transcription, 
transcript  processing  and  protein  synthesis  [78].  In  turn,  a  proportion  of  these  may  be 
associated  with  disease.  Therefore,  considerable  research  efforts  have  been  made  to 
identify SNPs which exert a functional consequence. For example, it has been estimated that 
15%  of  inherited  genetic  diseases  in  humans  are  caused  by  deleterious  mutations  that 
interfere  with  mRNA  splicing  [79].  Given  the  vast  number  of  SNPs  within  the  human 
genome, GWASs are often limited by the overwhelming number of markers to be screened 
[56]. However, this problem is usually overcome by prioritising markers of interest according 
to sequence-based features that can predict functional relevance [78], including distance 
from transcription factor start site, presence of flanking G and C nucleotides and sequence 
repetitiveness [80]. There has been much success in identifying and validating thousands of 
functional SNPs that are associated with a diverse range of human diseases [56].  
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Until recently, disease association studies focused predominantly on the role of SNPs [81]. 
The prevailing view had been that they were the most abundant source of genetic variation 
among humans [81] and were thus underlying the bulk of phenotypic diversity associated 
with disease [43]. As previously stated, it is widely accepted that osteoporosis is largely 
determined  by  genetic  factors;  however,  the  overwhelming  extent  of  this  contribution 
remains to be fully resolved. Moreover, evidence suggests that SNPs may only account for a 
small fraction of the overall risk [44]. For example, there are several known genetic markers, 
located within the vitamin D receptor (VDR), collagen type I alpha 1 (COLIA1), and  ESR1 
genes, which have been implicated in association with osteoporosis risk [22]; however, they 
only account for an estimated 5% of the total genetic contribution to the disease [82]. 
Consequently, it has become increasingly apparent that the remaining undiscovered genetic 
contribution may be due to other classes of genetic variation [44]. Therefore, over the past 
several years, a new source of genetic variation, defined as structural variation, has been 
extensively investigated. 
1.5.2.2 Structural Variation 
Structural variation is a broad term used to describe any type of genetic variation that alters 
chromosome structure [83]. It involves structural changes to DNA segments that typically 
span over a kilobase to several megabases [66]. Chromosomal rearrangements have long 
been shown to impact human health and disease, although until very recently, this impact 
was thought to be from rare, large-scale DNA changes, and reserved only for rare genomic 
disorders  (i.e.  Down’s  syndrome)  [83].  The  recent  development  of  array-comparative 
genomic  hybridisation  (aCGH)  and  other  high-throughput  genome-scanning  technologies 
facilitated the detection of smaller and more abundant chromosomal rearrangements [81].  
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Moreover, with the recognition of structural variation in otherwise healthy people [84], it 
has been widely anticipated for its contribution to some of the unexplained heritability 
underlying common complex diseases, such as osteoporosis [86]. However, the extent of 
functional  structural  variation  within  the  human  genome  is  only  just  beginning  to  be 
appreciated,  and  current  knowledge  appears  to  be  far  from  complete.  For  example, 
although currently published data may have defined more than 1500 independent sites 
representing 100 to 150 megabases of the human genome sequence as being structurally 
variable  [85],  comparison  of  these  datasets  shows  a  relatively  small  amount  of  overlap 
between studies [86]. Therefore, it is possible that only a fraction of the total amount of 
structural genetic variation has been ascertained to date. Structural variation exists in a 
variety of forms [66], which are broadly defined as either ‘balanced’ or ‘unbalanced’ [84], 
depending on whether the amount of diploid wild-type DNA actually changes [85]. Balanced 
variants  include  inversions,  insertions,  and  translocations  [84],  which  rearrange  the 
orientation of a DNA segment without actually changing the amount of DNA [87], while 
unbalanced  variants  include  deletions  and  duplications  [84],  which  directly  change  the 
amount of DNA [87]. Like other forms of genetic variation, structural alterations may exert a 
deleterious phenotypic consequence [62], presumably owing to changes involving functional 
genes. Furthermore, structural genetic variants can cover millions of nucleotides [83] and 
are thus likely to comprise of fully functional DNA sequences, which may already be subject 
to other forms of genetic variation. Interestingly, rapidly accumulating evidence suggests 
that structural genetic variants comprise a large proportion of SNPs [66]. Therefore, they are 
likely to make an even greater contribution to phenotypic diversity among humans, such as 
individual susceptibility to disease. 
    
25 
 
1.6 Copy Number Variation (CNV) 
CNV  is  the  most  common  source  of  structural  genetic  variation  [84].  It  involves  the 
duplication  or  deletion  of  DNA  segments  [84],  consequently  changing  the  structure  of 
chromosomes by joining together formally separated DNA sequences [88]. Therefore, CNV is 
used to describe any change to the original number of DNA copies [84]. It is still a relatively 
new area of genetic research, which is currently gaining widespread recognition from the 
scientific community. Therefore, the overwhelming majority of information pertaining to 
CNV remains to be fully resolved. 
1.6.1 Mechanism of CNV Formation 
Researchers have proposed a number of feasible mechanisms which may contribute to the 
formation of CNV [85]. Although the precise mechanism of formation is not yet completely 
understood, the fact that CNVs have been shown to preferentially occur near or within 
segmentally  duplicated  genomic  regions  has  provided  some  important  clues  as  to  their 
origins [89]. Segmental duplications are thought to arise through tandem replication of DNA 
sequences, followed by subsequent rearrangements that place the duplicated sequence at 
different  chromosomal  positions  [81].  During  the  metaphase  stage  of  cellular  meiosis, 
maternal and paternal chromosomes align using sequence homology as a guide to pair and 
initiate recombination of homologous pairs of chromosomes [88]. However, the presence of 
segmental  duplications  can  ‘trick’  the  recombination  machinery  to  initiate  a  cross-over 
event  where  it  normally  would  not  occur,  which  is  aptly  described  as  ‘non-allelic 
homologous recombination’ [88]. As a result, deletions or further duplications of the DNA 
can  occur  [88],  thereby  changing  the  wild-type  number  of  DNA  copies  and  promoting 
variability at a particular locus. Although the precise mechanism of CNV formation remains  
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to be fully elucidated, evidence suggests that CNVs can be either inherited or caused by de 
novo  mutations  which  can  arise  both  meiotically  and  somatically,  as  indicated  by  the 
observation  that  DNA  CN  can  vary  between  identical  twins  and  also  between  different 
organs and tissues within the same person [88]. 
1.6.2 Functional Consequence of CNV 
Despite being a complex phenomenon which remains to be fully understood, there are 
several lines of evidence which support the functional significance of CNV. Like other forms 
of  genetic  variation,  purifying  and  adaptive  natural  selection  pressures  appear  to  have 
influenced the frequency distributions of selective CNVs [84], indicating that they have at 
least some functional significance. Moreover, despite being less abundant than SNPs, CNVs 
generally account for far more nucleotide variation [84], which can be attributed to their 
sheer size. By encompassing large-scale segments of DNA [55], they are likely to overlap 
functional regions of the genome. In part, the functional consequence of CNV appears easily 
interpretable, considering how the human diploid genome is sensitive to changes affecting 
gene dosage [85]. Possessing the wild-type standard two copies provides a back-up for most 
genes should one be lost through mutation [83]. However, for a particular sub-set of genes 
known as haplo-insufficient and triplo-abnormal, two copies are essential for viability and if 
a copy is gained or lost, respectively, normal function cannot be sustained [83]. Although 
the functional consequence of CNV is largely expected to be a result of direct gene dosage 
effects, recent evidence indicates that the majority of known genes subject to CNV are not 
even located within the identified region of genetic variation [84]. Considering that a large 
proportion of the human genome, currently estimated at 12%, is subject to CNV [88], it has 
become increasingly recognised that non-coding regions may be as equally relevant as those  
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which  code  for  proteins  [90].  Therefore,  CNV  may  also  affect  genes  indirectly  through 
disruption of the regulatory mechanisms which control their expression [55]. Furthermore, 
studies have identified much of the genetic contribution influencing gene expression as 
being located proximal to the genes that actually exhibit the variation [91]. This signal is 
described as ‘cis’, which indicates that the variant is located within a regulatory sequence 
whose target gene is located on the same chromosome [71]. For example, studies have 
demonstrated that the disruption of long-range ‘cis’-acting regulatory elements constitute 
part of numerous common complex disease loci [91]. Despite the apparent importance of 
‘cis’-acting regulators, ‘trans’-acting may equally contribute to genetic expression variation 
[73].  Disruption  of  long-range  control  is  most  readily  identified  when  the  resultant 
phenotype is a loss-of-function change [91], which consequently is the most likely outcome 
of CNV [92]. 
1.6.3 CNVs and Disease 
It is clear than CNV plays a significant role in the genetic aetiology of numerous diseases, 
with evidence supporting models of both highly-penetrant rare variants [93] and common 
CN polymorphisms with small effect sizes [94]. CNVs can be deleterious due to a number of 
mechanisms, including formation of new alleles via changes in coding sequence, gain or loss 
of alleles via changes in gene dosage, or ‘cis’ and ‘trans’ position effects via changes in gene 
regulation  [95].  Moreover,  studies  have  observed  that  many  of  the  functional  DNA 
sequences  encompassed  by  CNVs  are  associated  with  biological  mechanisms  mediating 
immune  responsiveness,  cellular  metabolism,  and  membrane  surface  interactions, 
otherwise defined as ‘environmental sensor’ genes [84]. Although they are not necessarily 
critical  for  growth  or  development,  these  genes  facilitate  enhanced  perception  and  
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interaction  with  the  constantly-changing  environment  [84].  Therefore,  in  the  context  of 
common  complex  diseases,  such  as  osteoporosis,  this  could  explain  how  CNVs  can  be 
present  within  the  genome  of  an  otherwise  healthy  person  and  not  cause  the  disease 
directly, but instead contribute to enhanced susceptibility (i.e. low BMD, poor structural 
quality of bones and fracture risk) given exposure to specific environmental factors (i.e. the 
frailty associated with old age and the related propensity to fall). 
Rapidly-developing technologies such as aCGH platforms have led to recent successes in the 
identification  and  validation  of  thousands  of  heritable  CNVs  [84].  However,  there  are  a 
number of issues that complicate large-scale analyses of the role of CNV in disease. Perhaps 
most difficult is actually identifying which CNVs are causal in a given disease. The candidate 
gene approach is based on the assumption that if a gene is important for biological reasons, 
it  may  also  affect  the  trait  of  clinical  interest  [96].  For  example,  in  the  context  of 
osteoporosis, the genes that are involved in the key biological processes related to the 
regulation of bone (i.e. the hormonal endocrine system and the RANK/RANKL/OPG and Wnt 
signalling pathways) are expected to influence phenotypes related to osteoporosis risk (i.e. 
low  BMD,  poor  structural  quality  of  bones  and  fracture  risk).  However,  because  many 
candidate gene studies lack both sufficiently powered data from small sample sizes and 
replication groups with which to validate findings [43], the status of many CNVs in disease 
remain uncertain [89]. 
Although establishing a causal relationship between CNV and disease remains challenging 
for researchers [89], recent studies have demonstrated that known CNVs account for up to 
15% of the total genetic variation in gene expression [55]. Therefore, considering that gene 
expression is the most fundamental level at which the genotype gives rise to the phenotype  
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[67], and also that the full extent of CNV within the human genome has not yet been fully 
resolved [89]; CNVs may potentially contribute substantially to phenotypic diversity related 
to  individual  susceptibility  to  disease  [69].  Furthermore,  CNV  may  even  constitute  a 
substantial part of the undiscovered genetic contribution towards phenotypes related to the 
risk of osteoporosis [82], but further research is required. 
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1.7 Statement of Thesis 
1.7.1 General Purpose of Research 
Given what is already known about osteoporosis, gene expression, and CNV, the general 
purpose of this study is to investigate whether CNV of genomic regions, whose wild-type 
expression has previously been implicated with the regulation of bone, has an influence on 
the  regulation  of  the  surrogate  phenotype  for  osteoporosis,  BMD,  and  thus  whether  it 
influences the risk of developing the disease. 
1.7.2 Hypothesis 
Therefore, the hypothesis to be tested in this study is that CNV is associated with BMD. 
1.7.3 Aims of Study 
To address the hypothesis of this study, and to better elucidate the potential relationship 
between  CNV  and  osteoporosis  for  further  research,  the  main  aim  of  this  study  is  to 
examine the potential effect of two novel CNVs of the genes ESR1 and AXIN1, Variant_4512 
and  Variant_4912,  respectively,  in  relation  to  BMD,  in  a  population  cohort  study  of 
Caucasian women, between the ages of 18 and 83, from Australia and the UK. 
Furthermore, the specific aims of this study, with which the main aim will be addressed, are 
as follows: 
1) To attempt the accurate detection and quantitation of Variant_4512 and Variant_4912, 
respectively, in every subject of the study cohort, using relatively novel CNV genotyping 
techniques via qPCR combined with TaqMan chemistries, and the CN quantitation software, 
CopyCaller.  
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2) To examine the potential effect of Variant_4512 and Variant_4912, respectively, in the 
study cohort, in relation to three different BMD phenotypes; 1) raw measurement (g/cm
2), 
2) age-adjusted Z-score, and 3) controlled for several covariates, at three common skeletal 
locations of osteoporotic fracture; 1) lumbar spine, 2) total hip, and 3) femoral neck, using 
analyses of variance via the statistics software, SPSS. 
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Chapter 2: Materials and Methods 
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2.1 Materials 
2.1.1 Selection of CNVs for Study 
Table 1: Databases of Genomics and Bioinformatics used to Select CNVs for Study 
Item  Supplier 
Database of Genomic Variants (DGV)* 
The Centre of Applied Genomics, Canada, 
http://projects.tcag.ca/variation 
UCSC Genome Browser* 
University of California, Santa Cruz, 
http://www.genome.ucsc.edu 
*Human Genome Assembly (HGA) GRCh37/hg19 
2.1.2 gDNA Preparation 
Table 2: Source of gDNA Samples for Study Subjects 
Item  Supplier 
GENOS (STH-S) Cohort Study Sample Set 
Provided by Prof Timothy Spector, Dept. of 
Twin Research and Genetic Epidemiology,  
King’s College London UK and A/Prof Scott 
Wilson, Dept. of Endocrinology and 
Diabetes, SCGH Nedlands WA 
 
Table 3: Reagents for TE (Tris-EDTA) Buffer 
Item  Supplier 
Ethylenediaminetetraacetic Acid (EDTA)  AnalaR, Victoria, Australia 
Hydrochloric Acid (HCl)  APS Finechem, Australia 
Sodium Hydroxide (NaOH)  APS Finechem, Australia 
pH and Temperature Meter  TPS Pty Ltd., Australia 
Trizma Base (Tris)  Sigma-Aldrich, USA  
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2.1.3 qPCR (Real-Time Quantitative Polymerase Chain Reaction) 
Table 4: TaqMan CN Assays used to Amplify and Detect CNVs 
Item  Supplier 
20X Hs02308196_cn, 
AXIN1 CNV Variant_4912* 
Applied Biosystems by Life Technologies 
(ABI), Australia 
20X Hs04311774_cn,  
ESR1 CNV Variant_4512* 
ABI, Australia 
*DGV Variant ID (HGA GRCh37/hg19) 
Table 5: qPCR Reagents for TaqMan CN Assays 
Item  Supplier 
20X RNase P Reference Assays  ABI, Australia 
20X Genotyping Master Mix  ABI, Australia 
Nuclease-Free Water  Promega, USA  
 
Table 6: qPCR Instruments and Equipment 
Item  Supplier 
Microtubes, 0.6mL and 1.7mL  Axygen, Australia 
96-Well PCR Microplates  Axygen, Australia 
ABI 7900HT Fast Thermal Cycler  ABI, Australia 
Centrifuge  Rowe Scientific Pty Ltd., Australia 
MicroAMP Optical Adhesive Film   ABI, Australia 
MicroAMP 384-Well Reaction Plates  ABI, Australia 
Microcentrifuge  IEC, USA 
Plate Spinner  Janke & Kunkel, Germany 
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2.1.4 Analysis of Experimental Data 
Table 7: Method used for CN Prediction 
Item  Supplier 
CopyCaller Software, Version 2.0  ABI, Australia 
 
Table 8: Statistics Package used to Test Association of CNV and BMD 
Item  Supplier 
IBM SPSS Statistics, Version 20.0  IBM Corporations, USA 
 
2.1.5 General Laboratory Protocol 
Table 9: General Equipment used in Laboratory 
Item  Supplier 
Autoclave  Atherton, Victoria, Australia 
Ethanol  BioLab, Australia 
Gloves, Non-Sterile Latex  Ansell, Australia 
Pipettes  Gilson, USA 
Pipette Tips  Sarstedt and Labcon, USA 
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2.2 Methods 
Notes: 
a) This study investigated the potential effect of two different CNVs on BMD, and although 
the CNVs were analysed separately, all methods were applied in exactly the same manner, 
unless otherwise indicated. Therefore, in this thesis, the analyses of ESR1 CNV and AXIN1 
CNV are collectively described in the following general methods section. 
b) The dedicated contribution of Shelby Chew with laboratory technical assistance must be 
acknowledged. 
2.2.1 Selection of CNVs for Study 
2.2.1.1 Identification of Potential Osteoporosis Genes 
Genes that are potentially relevant to osteoporosis and its related phenotypes, including 
those  that  regulate  bone  turnover,  bone  mass,  BMD,  and  fracture  risk,  were  broadly 
identified  via  an  extensive  interrogation  of  various  scientific papers  and  review  articles. 
Focus was eventually directed towards two main resources; a collaborative meta-analysis 
implicating 150 candidate genes with osteoporosis and fracture [97], and a meta-analysis of 
five GWAS implicating 20 genetic loci in association with BMD [98]. Genomic regions of 
interest were short-listed for further investigation based on subjective criteria. Firstly, they 
had to have a significant association to a bone trait, such as bone turnover, bone mass, 
BMD, or fracture risk, that was reported in a discovery set, and which had been confirmed in 
further  replication  sets.  Secondly,  they  could  be  mapped  to  SNPs  implicated  with bone 
traits.  As  a  result,  many  of  the  genomic  regions  of  interest  selected  for  this  study  had 
already been firmly implicated with phenotypes related to osteoporosis risk. The genomic  
37 
 
regions of interest in this study were short-listed as follows; ARHGAP1, AXIN1, ANAPC1, 
C17orf53,  C18orf19,  DCDC5,  EIF4G3,  ESR1,  FOXL1,  GPR177,  LRP5L,  NTAN1,  MEPE,  OPG, 
RANKL, SOX9, STARD3NL, TNFSF11, and ZBTB40. 
2.2.1.2 Identification of CNVs 
CNVs that have been detected for the genomic regions of interest were identified via the 
DGV. It was initially intended for CNVs to be selected as potential candidates for this study 
based on subjective criteria; however, slight modifications had to be made. Firstly, for this 
study to have been a true replication study in terms of CNV detection, the discovery cohort 
from which the CNV was initially detected should have been representative of the cohort 
that would be used in this current study [99]. Therefore, both sets of subjects should have 
shared  similar  distributions  of  characteristics  (i.e.  age,  gender,  and  ethnicity).  However, 
considering that no discovery set was comprised exclusively of Caucasian women between 
the ages of 18 and 83 [100], as was used in this current study, this particular point of criteria 
could not be fulfilled. 
Secondly, a CNV observed in 10% or more of the analysed discovery cohort was estimated 
as a common frequency [101], and was thus interpreted as likely to be common in any 
similar human population. However, as previously stated, the population in this current 
study  was  not  similar  to  any  discovery  population.  Nonetheless,  these  CNVs  were  still 
selected for this study because they were interpreted as common variants; and considering 
that common variants are expected to constitute the genetic contribution of osteoporosis 
(Refer  to  Section  1.4.1),  they  appeared  extremely  relevant  for  this  study.  The  CNVs  of 
interest in this study were short-listed as follows;  
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Table 10: Short-List of Potential Candidate CNVs for Study 
Gene  CNV*  Reference 
Frequency Information 
Sample 
Size 
Observed 
Gain 
Observed 
Loss 
Total 
(%) 
ANAPC1  30997  Perry et al. (2008)  30  4  0  13.3 
AXIN1  4912  Wong et al. (2007)  95  0  19  20 
C18orf19  73114  Conrad et al. (2009)  39  0  17  43.6 
EIF4G3  84113  Matsuzaki et al. (2009)  90  0  10  11 
ESR1  4512  Wong et al. (2007)  95  20  0  21 
LPR5L  7342  de Smith et al. (2007)  50  22  4  52 
*DGV Variant_ID (HGA GRCh37/hg19) 
2.2.1.3 Critical Evaluation of CNVs 
Genes corresponding to the potential candidate CNVs were each investigated in further 
detail to critically evaluate their potential role in osteoporosis. There had to be reasonable 
hypotheses with supporting evidence as to how their activity is involved in bone regulation, 
and therefore how CNV could potentially disrupt this normal activity and influence the risk 
of developing osteoporosis. Fundamental biological information was accessed via the UCSC 
Genome  Browser.  Bioinformatics  provided  valuable  insights  into  each  gene  (i.e.  what 
products they encode, what biological pathways they are involved with, what factors they 
interact with, etc.), which helped elucidate the extent of their involvement in the regulation 
of bone, and thus their potential role in phenotypes related to osteoporosis. 
CNVs were ultimately selected for this study based on subjective criteria. Firstly, previous 
studies had to have implicated the normal, human diploid wild-type expression of the gene 
which they encompass with phenotypes related to osteoporosis, such as bone turnover, 
bone mass, BMD, and fracture risk. Secondly, their incidence within the discovery cohort  
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had to be common (i.e. a CNV frequency of 10% or greater), and they were thus defined as a 
common variant. Thirdly, evidence had to confirm that the gene which they encompass is 
either directly or indirectly relevant to the normal regulation of human bone. Therefore, the 
CNVs  that  were  ultimately  selected  for  analysis  in  this  study  were  Variant_4512  and 
Variant_4912 of the genes ESR1 and AXIN1, respectively. 
2.2.2 Sample Preparation 
2.2.2.1 Study Subjects 
Subjects  analysed  in  this  study  were  taken from  the  established  GENOS  (STH-H)  cohort 
study, which is comprised of 769 Caucasian women across 335 families that were recruited 
in  Australia  and  the  UK  [100].  This  family-based  population  includes  subjects  from  two 
separate studies of the genetics of osteoporosis in twins and siblings, respectively [100]. All 
subjects from the cohort provided written informed consent, and the institutional ethics 
committees of the participating institutions approved the experimental protocol. Along with 
blood samples, clinical phenotype data were obtained for each subject. DXA BMD (g/cm
2) 
was assessed at the lumbar spine L1-L4, and the total hip, which includes an area from the 
femoral neck to just below the lesser trochanter [100]. Because the age range of the cohort 
is between 18 and 83 [100], the BMD data (g/cm
2) were adjusted for age by conversion to 
BMDZs. A BMDZ provide a correction of BMD for age by defining its number of SDs above or 
below the mean of an age-adjusted control population [30]. The BMDZs for this cohort were 
calculated using published normal-range data for the analysed skeletal sites [100]. Subjects 
also  had  their  height  and  weight  recorded,  and  answered  questions  pertaining  to  their 
medical, gynaecological, and lifestyle histories [100]. However, the clinical phenotype data 
used to characterise the cohort in this study related exclusively to BMD (g/cm
2) and its  
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related BMDZ at the lumbar spine, total hip, and femoral neck, and also age, height, and 
weight, which were used to generate the additional variables of age
2 and BMI. Table 11 
summarises the clinical BMD phenotype data of the cohort study in terms of mean
 ± SD. 
Table 11: Clinical BMD Phenotype Data for Cohort Study 
Clinical BMD Phenotype  Mean
 ± SD 
Spine BMD (g/cm
2)  0.851 ± 0.154 
Total Hip BMD (g/cm
2)  0.789 ± 0.126 
Femoral Neck BMD (g/cm
2)  0.702 ± 0.132 
Spine BMDZ  - 0.794 ± 1.260 
Total Hip BMDZ  - 0.593 ± 0.930 
Femoral Neck BMDZ  - 0.432 ± 1.079 
 
2.2.2.2 gDNA Dilution 
Biological samples were provided as liquid gDNA, which had been extracted and purified 
from EDTA whole blood  [100], and diluted to 20X stock solutions (20ng/µL) prior to this 
study. Stock solutions were stored in 96 -well PCR microplates in a  -86
oC UltraFreezer. For 
every gDNA sample analysed in this study, an aliquot of the 20X stock solution was taken 
and further diluted to 5ng/µL in new 96-well PCR microplates using 1 X TE buffer, pH 8.0 
(Refer to Appendix), in accordance with the protocol specifications of ABI for their TaqMan 
CN Assays [102]. Dilution volumes were dependent on every reaction containing 2µL of 
gDNA (5ng/µL), as specified by ABI, and also that each biological sample was analysed as 
two  technical  replicates.  It  must  be  acknowledged  that  ABI  recommends  using  four 
replicates for each sample. However, faulty laboratory instrumentation created unforseen 
time constraints in this study. Furthermore, given the reasonably large sample set and the  
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relative  expense  of  ‘off-the-shelf’  TaqMan  CN  Assays,  coupled  with  the  fact  that  every 
subject had to be genotyped in two CNV analyses, running only one 384-well qPCR reaction 
plate at a time, it was necessary to modify the number of technical replicates from four to 
two. Dilution volumes were routinely calculated as follows; 
Figure 1: Routine Calculations for gDNA Dilution Volumes    
Total Dilution Volume (µL) =  
 Number of Reactions per Sample (+ 0.3 Excess Reactions to Provide for Error)  
× Volume of gDNA Required per Reaction 
DNA Dilution Concentration (ng/µL) =  
 Concentration of gDNA Required per Reaction (ng/µL)  
× Total Dilution Volume (µL) 
DNA Dilution Volume (µL) =  
DNA Dilution Concentration (ng/µL)  
Concentration of gDNA per Sample (ng/µL) 
TE Buffer Dilution Volume (µL) = 
Total dilution volume (µL) – DNA dilution volume (µL) 
2.2.3 Detection of CNV 
CNV was detected via duplex qPCR using the ABI 7900HT Fast thermal cycler combined with 
TaqMan Assay detection chemistry. Every gDNA sample was analysed in technical duplicate 
in 384-well reaction plate format for both ESR1 CNV and AXIN1 CNV in separate analyses. In 
every  reaction,  a  target  gDNA  sequence  specific  to  the  CNV  of  interest  was  quantified 
alongside an endogenous reference gDNA sequence specific to the RNase P RNA component  
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H1 (H1RNA) gene (RPPH1), which is known to be present as the wild-type number of copies 
(i.e. CN2) in the human diploid genome, and does not display CNV [103]. CNV genotypes 
were subsequently determined using the computer software program, CopyCaller, which 
performed comparative CT (ΔΔCT) relative quantitation analysis of the qPCR data from the 
TaqMan Assay experiments. This method of relative quantitation determined the relative 
CN of the target CNV (ESR1 and AXIN1, respectively) in every gDNA sample, normalised to 
the known CN2 of the reference gene. 
2.2.3.1 Overview of qPCR 
qPCR, like a conventional PCR, involves the amplification of specific or complementary DNA 
sequences [104]. In a conventional PCR, the amplified product is detected and measured by 
‘end-point’  analysis,  such  as  agarose  gel  electrophoresis  or  DNA  sequencing  [104].  In 
contrast, qPCR enables the accumulation of amplified product to be detected and measured 
as  the reaction  progresses  [104],  hence  it  being  referred to  as  ‘real-time’  analysis.  This 
function is made possible by a molecule in the reaction that reports  an increase in the 
amount of DNA amplicon with a proportional increase in fluorescent signal [104]. Moreover, 
specialised  thermal  cyclers,  which  are  equipped  with  fluorescence  detection  modules, 
monitor  and  measure  the  fluorescence  as  amplification  progresses  [105].  During  each 
amplification cycle, the amount of template DNA increases exponentially (i.e. doubles in 
amount), but as the reagents become used up, the reaction slows and enters a plateau 
phase  [106].  The  level  of  fluorescent  initially  cannot  be  detected  from  that  of  the 
background fluorescence [106]. However, enough DNA amplicon is eventually produced to 
yield a detectable signal. The amplification cycle in which this occurs is the cycle threshold 
(CT) [106]. Considering that the CT is measured during the exponential phase, when the  
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reagents are not limiting, qPCR can accurately calculate the amount of DNA that was initially 
present in the reaction [106]. In view of this, if a large amount of DNA is present at the start 
of the reaction, fewer amplification cycles will be required for the fluorescence to rise above 
background levels and hence the CT value will be low [107]. Conversely, if a small amount of 
DNA is present, more amplification cycles will be required for the fluorescence to rise above 
background levels and hence the CT value will be high [107]. 
There are many advantages for using ‘real-time’ chemistries over traditional, ‘end-point’ 
PCR  methods.  Firstly,  qPCR  provides  both  qualitative  and  quantitative  information  with 
increased precision, accuracy, and resolution, over a wide dynamic range [108]. Secondly, 
results  can  be  measured  without  agarose  gel  electrophoresis  or  DNA  sequencing  [104], 
thereby  reducing  experiment  time  and  increasing  laboratory  throughput.  Thirdly,  it  is  a 
closed-tube system which reduces the opportunities for contamination and eliminates the 
need for post-amplification processing [109]. 
2.2.3.2 Overview of TaqMan Assay Detection Chemistry 
The qPCR experiments undertaken in this study used TaqMan-based (i.e. hydrolysis-based 
[108]) chemistries to detect changes in DNA quantity. At the initial stage of qPCR, when the 
gDNA denatures and the set of assay primers anneal to their specific target sequences, an 
oligonucleotide  probe  anneals  specifically  to  its  complementary  sequence  between  the 
forward and reverse primer binding sites [108; 110; 111]. This oligonucleotide is labelled 
with a fluorescent reporter dye at the 5’ end and a quencher dye at the 3’ end [111]. When 
the probe is intact, the reporter is in close proximity to the quencher and the fluorescent 
signal emitted by the reporter as it is excited by the thermal cycler’s light source via förster 
resonance energy transfer (FRET) is low [108; 110; 111]. During amplification, as Taq DNA  
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polymerase extends from the primers, the 5’ exonuclease activity of the enzyme will cleave 
the  annealed  probe,  separating  the  reporter  dye  from  the  quencher  dye,  relieving  the 
quenching effect and thus increasing the fluorescent signal [108; 110; 111]. 
The main advantage of TaqMan-based chemistries over other detection chemistries is that 
the fluorescent signal is generated only when there is specific hybridisation of the probe to 
the target DNA sequence [108]. Another advantage is that TaqMan probes can be labelled 
with different, spectrally distinct reporter dyes [110]. Therefore, reactions can be performed 
as duplex, rather than singleplex. In a singleplex reaction, each target sequence of interest is 
analysed individually in separate reactions [110]. Conversely, a duplex reaction allows for 
the amplification of multiple target sequences within a single tube [110]. Therefore, duplex 
reactions confer certain advantages over singleplex reactions. Firstly, there is a reduction in 
the  amount  of  starting  template  DNA  required  [111].  Secondly,  there  is  an  increased 
laboratory  throughput,  with  an  associated  reduction  in  costly  reagent  wastage  [111]. 
Thirdly,  there  is  a  minimisation  of  sample  handling  [111],  which  reduces  potential 
opportunities for cross-contamination. 
2.2.3.3 Selection of TaqMan Assays used in Study 
The TaqMan CN Assays used in this study were selected via the ABI website’s TaqMan CNV 
Assay search tool. A multitude of pre-designed assays for human CNV were available to 
target  a  range  of  different  locations  across the  CNVs  of  interest  in this  study.  The two 
TaqMan CN Assays used for the analyses of ESR1 CNV and AXIN1 CNV, respectively, were 
ultimately selected based on subjective criteria. Firstly, it had to target a region somewhere 
in the middle of the CNV, so as to ensure adequate coverage across the genomic region of 
interest in terms of both annealing and amplification specificity. Secondly, it had to target a  
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region near the vicinity of SNPs that have been implicated with BMD. The two TaqMan CN 
Assays used to detect the CNVs of ESR1 and AXIN1, respectively, were as follows: 
Figure 2: Summary of TaqMan CN Assays Selected for Study 
CNV Assay # 1 
Assay ID: Hs04311774_cn 
Assay Information: 
Location: Chr.6:15207001 on NCBI Build 37 
Cytoband: 6q25.1c 
Species: Homo sapiens 
Amplicon Length: 88 bp 
Target Gene Details: 
Gene Name: Estrogen receptor 1 
Gene Symbol: ESR1 
NCBI Location: Chr.6:152011631 – 152424409 
Assay Gene Location: Within Intron 2 
Target CNV Details: 
DGV Version: 37,hg 19.v10 
DGC Locus Location: Chr.6:151959784 – 152182026 
Target Variation ID: Variant_4512 
Target Variation Location: Chr.6:151959784 – 152182026 
Known Genes: ESR1 
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CNV Assay #2 
Assay ID: Hs02308196_cn 
Assay Information: 
Location: Chr.16:364597 on NCBI build 37 
Cytoband: 16b13.3f 
Species: Homo sapiens 
Amplicon Length: 110 bp 
Target Gene Details: 
Gene Name: Axin 1 
Gene Symbol: AXIN1 
NCBI Location: Chr.16:337440 – 402464 
Assay Gene Location: Within Exon 3 
Target CNV Details: 
DGV Version: 37,hg 19.v10 
DGC Locus Location: Chr.16 :60001 – 2870536 
Target Variation ID: Variant_4912 
Target Variation Location: Chr.16:333375 – 526226 
Known Genes: 
AXIN1, TMEM8A, LOC100134368, RAB11FIP3, PDIA2, MRPL28, DECR2 and NM4 
Each  TaqMan  CN  Assay  contained  two  unlabelled  primers  for  amplifying  the  target 
sequence of interest and one TaqMan Minor Groove Binder (MGB) probe for detecting the 
target sequence of interest [102]. The detection probe consisted of a FAM reporter dye 
attached to the 5’ end, and a non-fluorescent quencher and MGB attached to the 3’ end 
[102].  Given  that  every  reaction  had  to  simultaneously  amplify  and  detect  a  reference 
sequence, TaqMan CN Reference Assays also had to be purchased and were selected to 
target a gDNA sequence specific to the RNase P RNA component H1 (H1RNA) gene (RPPH1),  
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located on chromosome 14, cytoband 14q11.2. This gene is known to be present as two 
copies  and  express  at  a  constant  level  in  the  human  diploid  genome  [103].  This  is  the 
TaqMan Reference CN Assay recommended by ABI for their TaqMan CN Assays, for human 
CNV analysis [112]. Each TaqMan CN Reference Assay contained two unlabelled primers for 
amplifying  the  reference  sequence  and  one  TaqMan  TAMRA  probe  for  detecting  the 
reference sequence [102]. The detection probe consisted of a VIC reporter dye attached to 
the 5’ end and a TAMRA quencher attached to the 3’ end [102]. 
2.2.3.4 CNV Genotyping via qPCR 
Every qPCR reaction in this study contained 2µL of diluted gDNA (5ng/µL) and 8µL of a 
reaction mixture, consisting of 5µL of TaqMan Genotyping Master Mix, 0.5µL of TaqMan CN 
Assay, 0.5µL of TaqMan CN Reference Assay, and 2µL of Nuclease-Free Water. For every 
384-well reaction plate run, a master mix of reaction mixture was prepared first. It was 
prepared in microtubes and then transferred to strip-tubes for delivery into the reaction 
plate via multichannel pipette. The volumes of the different components were calculated 
based on the total reaction mixture volume (8µL) and the number of reactions to be run (n), 
including excess volume to provide for the loss which occurs during reagent transfer. Every 
gDNA sample was analysed in technical duplicate. Two non-template controls (NTCs) were 
also run on every reaction plate, containing 2µL of TE Buffer rather than gDNA, to expose 
potential contamination of reagents.  For every 384-well reaction plate run throughout this 
study, each 10µL reaction volume was routinely prepared in accordance with the protocol 
specifications outlined by ABI for their TaqMan CN Assays [102], which were as follows; 
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Table 12: qPCR Reaction Mixture for TaqMan CN Assays 
REACTION MIXTURE COMPONENT  1 REACTION (μL)  n REACTIONS (μL) 
2X TaqMan Genotyping Master Mix  5  n x 5 
20X TaqMan CN Assay  0.5  n x 0.5 
20X TaqMan CN Reference Assay  0.5  n x 0.5 
Nuclease-Free water  2  n x 2 
TOTAL VOLUME  8  n x 8 
5X gDNA (5ng/μL)  2  n x 2 
TOTAL VOLUME  10  n x 10 
 
Likewise, thermal cycling conditions were also routinely run in accordance with protocol 
specifications outlined by ABI for their TaqMan CN Assays [102], which were as follows; 
Table 13: qPCR Thermal Cycling Conditions for TaqMan CN Assays 
STAGE  DURATION  TEMPERATURE  NUMBER OF CYCLES 
Hold  10 minutes  95
oC  1 
Denaturation  15 seconds  95
oC 
40  Annealing and 
Extension 
1 minute  60
oC 
 
2.2.4 Quantitation of CNVs 
2.2.4.1 Overview of CopyCaller 
Once  both  target  CNVs  had  been  respectively  amplified  and  detected  via  duplex  qPCR 
combined with TaqMan Assay chemistry, the resultant CT values were analysed using the 
computer software program, CopyCaller. This program performs a comparative CT (ΔΔCT)  
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relative quantitation analysis of the qPCR data from the TaqMan CN Assay experiment [113]. 
In brief, an in-built algorithm automatically determines the CN of the target sequence in 
each  test  gDNA  sample,  along  with  related  confidence  measures.  The  program  first 
calculates the difference between the CT values (ΔCT) of the target sequence (of unknown 
CN) and the endogenous reference sequence (of known and invariant CN) [113]. Then, the 
program compares the ΔCT values of each test sample with that of a calibrator sample that 
contains a known number of copies of the target sequence [113]. Alternatively, the analysis 
can be performed without the use of a calibrator sample, provided that the predicted CN 
distribution, and hence the most frequent CN expected, is known [113]. In this study, due to 
time  constraints,  a  control  sample  could  not  be  identified  for  either  CNV.  Therefore, 
analyses were performed without the use of a calibrator sample. The most frequent CN 
expected for both genes was the wild-type number of copies expected in the human diploid 
genome (i.e. CN2) [83]. 
The quantitative analysis performed by CopyCaller is based on a theoretical model that 
describes the exponential nature of the qPCR process [113]. In theory, as the number of 
gene  copies  increases,  the  difference  between  successive  CT  values  decreases  [107].  In 
practice, however, deviations from the ideal may occur, where wells produce ΔCT values 
that differ significantly from the mean of all applicable wells [113; 114]. Such deviations can 
be attributed to samples that amplify insufficiently or not at all due to experimental error, 
such as pipetting inaccuracy, contamination, thermal fluctuations, the binding behaviours of 
PCR primers and TaqMan probes, or the starting gDNA concentration of a sample [113; 
114]. Nonetheless, the software combined with TaqMan Assay chemistry handles deviations 
from the ideal statistical model through the use of an endogenous reference, which detects  
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and removes invalid data and outliers contributing to ΔCT variation [113]. For example, the 
program  removes  background  fluorescence  by  normalising  the  CT  value  of  each  target 
sequence with that of the corresponding reference sequence by calculating the well-level CT 
difference between each combination [113]. Moreover, a VIC CT value greater than 32.0 
indicates  failed  amplification  and  the  sample  is  therefore  defined  as  having  an 
‘undetermined’ CN [113]. 
CopyCaller is the method of quantitative analysis recommended by ABI for their TaqMan CN 
Assays [112]. The program is highly advantageous for quantitative CNV analysis compared to 
other methods of analysis. Firstly, CopyCaller limits the amount of human manipulation 
needed  to  genotype  gDNA  samples  compared  to  manually  calculating  the  relative 
expression ratio of a target sequence to a reference sequence via the Pfaffl equation. The 
Pfaffl  equation  is  extremely  time-consuming  and  highly  susceptible  to  human  error, 
particularly  when  dealing  with  large  sample  sets.  Moreover,  CNV determination  via  the 
Pfaffl equation ultimately depends on the judgement of the experimenter by subjecting the 
resultant expression ratios to a subjective ‘binning’ method, which imposes defined zones in 
which the CNV statuses fall [111]. Secondly, CopyCaller facilitates the easy expedition of 
qPCR data [113], eliminating the need for time-consuming and human error-prone manual 
data entry into the template. The resultant CT values from qPCR are presented in a .txt file, 
which can be exported from a compatible ABI thermal cycler straight into CopyCaller [113], 
thereby  reducing  the  chance  for  data  mismanagement.  That  being  said,  some  data 
manipulation of the .txt file is still required before it is analysed by the program, given that 
the resultant CT value from qPCR are automatically presented in such a way that technical 
replicates corresponding to a single sample are each represented as if they are different,  
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individual samples. Therefore, by changing the ‘sample name’ in the .txt file, replicate data 
can  be  combined  to  generate  a  single  CN  call  for  the  one  sample,  along  with  related 
confidence measures. Whilst the ABI thermal cycler software already has a feature  that 
enables  the  experimenter  to  indicate  which  wells  of  the  reaction  plate  are  sample 
replicates, this is also a time-consuming and human error-prone process. It would be ideal if 
no data manipulation was required and hence a future recommendation for ABI would be to 
refine their presentation of CT values, so that replicate data may be efficiently combined 
automatically rather than manually, in what is an otherwise quality product. 
2.2.5 Critical Evaluation of Experimental Data 
2.2.5.1 Tests of Reliability and Reproducibility 
Once every sample has been genotyped for the target CNV of ESR1 and AXIN1, respectively, 
they had to be approved for use in statistical analysis based on subjective criteria. Firstly, 
the distribution of qPCR data between the two technical replicates of a sample had to be 
consistent. For each pair of replicates, the mean, SD, and standard error (SE), of the FAM 
and VIC signal intensities on the CT scale were calculated and plotted using the computer 
software program, Microsoft Excel. Although less than 0.5 SDs above or below the mean is 
the ideal measure of confidence [115], this threshold was expanded to less than 1.0 SDs for 
this study to allow for a certain degree of leniency due to limiting gDNA stocks, limiting 
reagents, and additional time constraints. If a sample had an obviously large SD for its mean, 
exceeding 1.0, it was flagged for a second round of genotyping. Secondly, both replicates of 
a  sample  had  to  have  a  viable  CN  predicted  by  CopyCaller  (i.e.  an  actual  number).  An 
‘undetermined’  CN  indicated  that  the  reaction  most  likely  failed  due  to  an  insufficient 
amount of starting gDNA template [113]. Conversely, an unreasonably large CN indicated  
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that  the  reaction  most  likely  contained  an  excessive  concentration  of  starting  gDNA 
template  [113].  Therefore,  if  either  replicate  yielded  a  CN  that  was  ‘undetermined’  or 
unusually large, the sample was flagged for a second round of genotyping. Thirdly, both 
replicates  of  a  sample  had  to  have  the  same  CN  predicted  by  CopyCaller,  which  also 
matched up with the CN yielded when replicate data were combined in the CopyCaller 
template to represent the one sample. Reproducible data signified a reliable result, so if 
there was consistency in CN calls between replicates, the sample was defined as having a 
‘confirmed’ CN. Conversely, if there was discrepancy in CN calls between replicates, the 
sample was defined as having an ‘unconfirmed’ CN and was thus flagged for a second round 
of genotyping. Lastly, there were 11 biological replicates for 9 specific subjects that were 
randomly included in the sample set, which served as internal calibrators to validate or 
refute CN calls. 
2.2.5.2 Prioritisation of Samples with ‘Unconfirmed’ CN from First Round of Genotyping 
After  the  first  round  of  genotyping,  reagents  for  the  ESR1  CNV  were  not  limiting  and 
therefore every sample with an ‘unconfirmed’ CN for the ESR1 CNV could be analysed by 
qPCR and CopyCaller again. Conversely, due to limiting reagents for the AXIN1 CNV, as well 
as limiting gDNA stocks and additional time constraints, samples with an ‘unconfirmed’ CN 
for  the  AXIN1  CNV  had  to  be  prioritised  based  on  the  likelihood  that results  would  be 
reliable and reproducible when analysed again (Refer to Section 2.2.5.1). Firstly, despite the 
discrepancy in CN calls from the first round of genotyping, both technical replicates of a 
sample had to have yielded an actual CN (i.e. not ‘undetermined’ by CopyCaller). If either 
replicate yielded an ‘undetermined’ CN, it was conceded that its reaction had failed and 
would  most  likely  fail  again,  and  the  sample  was  therefore  completely  eliminated  from  
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further analysis of the subject cohort. Secondly, the CN statuses observed from the first 
round of genotyping had to be reasonable within the context of this study, considering that 
variation from the apparent wild-type CN of the AXIN1 gene in a human diploid genome 
(CN2) was expected to represent either heterozygous loss (CN1) or gain (CN3); and more 
specifically, the AXIN1 CNV Variant_4912 constitutes a CN loss (CN1). If the aforementioned 
criteria were met, it would indicate that the TaqMan CN Assay experiments had worked and 
the gDNA stocks were of sufficient quality and quantity for a second round of genotyping. 
There was no point in wasting limiting reagents on limiting gDNA stocks if there was not a 
strong likelihood of yielding a ‘confirmed’ CN. 
2.2.5.3 Prioritisation of Samples with ‘Unconfirmed’ CN from Second Round of Genotyping 
After the second round of genotyping, samples which still had an ‘unconfirmed’ CN for ESR1 
or AXIN1, respectively, were further prioritised for use in statistical analysis. Due to limiting 
gDNA stocks, limiting reagents, and additional time constraints, a third round of genotyping 
was simply unfeasible. Moreover, it was important to salvage as many subjects as possible 
for statistical analysis, so that the sample size would be large enough to attain sufficient 
statistical power, thereby increasing the likelihood of finding statistical significance [116]. 
Therefore, the remaining samples with an ‘unconfirmed’ CN for ESR1 or AXIN1, respectively, 
were subjectively approved for statistical analysis based on the level of confidence that was 
estimated by CopyCaller. The program requires a minimum of four technical replicates per 
sample  to  provide  a  confidence  score  for  a  CN  call  [113].  At  this  point,  the  remaining 
‘unconfirmed’  samples  had  been  analysed  a  total  of  four  times  (i.e.  two  rounds  of 
genotyping  as  two  technical  replicates).  Therefore,  despite  the  discrepancy  in  CN  calls, 
replicate data were combined per sample to yield a single CN call with a related measure of  
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confidence.  Although  a confidence  score  between  0.99  and 1.0  is  the ideal  measure  of 
confidence [113], this threshold was expanded to between 0.70 and 1.0 for this study, to 
allow for a certain degree of leniency due to limiting gDNA stocks, limiting reagents, and 
additional time constraints, and so that the maximum possible number of samples could be 
approved for statistical analysis. 
2.2.6 Statistical Analysis of Experimental Data 
2.2.6.1 Consolidation of Genotype and Phenotype Data 
Prior to tests of normality and association via SPSS, both the genotype and phenotype data 
for every subject had to be consolidated into a common Excel file via the computer software 
program, Microsoft Access (i.e. specifically, two separate files for ESR1 CNV and AXIN1 CNV, 
respectively). The data required for statistical analysis were the observed CNV genotypes 
from this current study and the BMD measurements taken from previous cohort studies. 
Data had been recorded across several different Excel files,  defined by several different 
coded identification numbers pertaining to each subject. Specifically, for each subject, a 
GENOS (STH-S) cohort number corresponded to the genotype data and two identification 
numbers pertaining to each individual and their family, respectively, corresponded to the 
phenotype data. Each subject could be identified according to all three of these unique 
numbers. Merging both the genotype and phenotype data into a common source of access 
improved  traceability  and  reduced  potential  mismatches,  which  facilitated  the  easy 
expedition of selected data into new Excel templates to be exported into SPSS for statistical 
analysis.  
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2.2.6.2 Tests of Normality via SPSS 
For each analysis of the association between CNV genotype data (i.e. for ESR1 and AXIN1, 
respectively) and selected BMD phenotype data (Refer to Section 2.2.2.1), the dataset was 
examined  for  normality  via  SPSS.  Several  tests  of  normality  were  conducted,  which 
compared the selected sample data to a normal distribution with the same mean and SD 
[119]. The Shapiro-Wilk test of normality tested the null hypothesis of a normally distributed 
population [119]. Deviations from normality were statistically significant if the p-value was 
less than the 0.05 significance level, in which case the null hypothesis of normal distribution 
was rejected. Conversely, if the p-value was greater than the 0.05 significance level, the null 
hypothesis of normal distribution was not rejected, thereby indicating normality. Moreover, 
normally  distributed  data  would  allow  association  analysis  to  be  conducted  using  a 
parametric  test  [120].  The  results  of  the  Shapiro-Wilk  test  were  further  confirmed  by 
visually screening both Normal Quantile-Quantile (Q-Q) and Box Plots, which are graphical 
means  of  determining  the  level  of  normality  [119].  The  Normal  Q-Q  Plot  for  logistic 
regression residuals compared the observed dataset with the expected values for a normal 
distribution. It highlighted where observed data points deviated from the expected trend-
line, and hence did not display normal distribution; and conversely, where observed data 
were consistent with the expected trend-line, and hence contributed to normal distribution. 
The Box Plot showed the consistency of the dataset, highlighting where obvious outliers 
may have skewed the distribution away from normality; and conversely, where the box plot 
was symmetrical and evenly spaced, suggesting normal distribution.  
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2.2.6.3 Tests of Association via SPSS 
Tests of association between the CNV genotype data (i.e. ESR1 and AXIN1, respectively) and 
selected BMD phenotype data (Refer to Section 2.2.2.1) were conducted via SPSS. Assuming 
normally distributed data, three different parametric tests could be performed, depending 
on  the  number  of  observed  CNV  genotype  groups  (i.e.  independent  variable)  and  the 
selected BMD phenotype (i.e. dependent variable). The precondition of each test was the 
Levene’s Test for Equality of Error Variances, which assessed the variance homogeneity. The 
Levene’s Test tested the null hypothesis of equal error variance for BMD across the different 
CNV genotype groups [119], which was not rejected if the p-value was greater than the 
significance level of 0.05, indicating that the assumption of equal variances was met. 
Firstly, the potential effect of ESR1 CNV in relation to BMD (g/cm
2) and its related BMDZ was 
tested using a One-Way ANOVA Test of Between-Subject Effects. This technique is typically 
used to compare the means of at least three different sample groups [119]. Therefore, it 
was  appropriate  for  testing  the  potential  effect  of  ESR1  CNV,  considering  that  three 
different CNV genotypes were observed; CN loss (CN1), wild-type (CN2), and CN gain (CN3). 
The ANOVA test tested the null hypothesis that the difference in mean BMD between the 
three CNV genotype groups was no greater than that due to normal variation of subjects’ 
characteristics, and error in their measurement [119]. The null hypothesis was rejected if 
the p-value was less than the 0.05 significance level, which would therefore indicate that 
there  was  evidence  of  a  statistically  significant  association  between  CNV  and  BMD. 
Conversely, if the p-value was greater than the 0.05 significance level, the null hypothesis of 
equal means was not rejected, which would therefore indicate that there was no evidence 
of a statistically significant association between CNV and BMD.  
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Secondly, the potential effect of AXIN1 CNV in relation to BMD (g/cm
2) and the related 
BMDZ was tested using an Independent-Sample T-test. This technique is typically used to 
compare the means of two different sample groups [119]. Therefore, it was appropriate for 
testing  the  potential  effect  of  AXIN1  CNV,  considering  that  only  two  different  CNV 
genotypes had available phenotype data for statistical analysis; wild-type (CN2) and CN gain 
(CN3). The T-test tested the hypothesis that the difference in mean BMD between the two 
CNV  genotype  groups  was  no  greater  than  that  due  to  normal  variation  of  subjects’ 
characteristics, and error in their measurement [119]. The null hypothesis was rejected if 
the p-value was less than the 0.05 significance level, which would therefore indicate that 
there  was  evidence  of  a  statistically  significant  association  between  CNV  and  BMD. 
Conversely, if the p-value was greater than the 0.05 significance level, the null hypothesis of 
equal means was not rejected, which would therefore indicate that there was no evidence 
of a statistically significant association between CNV and BMD. 
Lastly, the potential effect of several covariates (i.e. age, age
2, height, weight, and BMI) in 
relation  to  the  association  between  CNV  (i.e.  ESR1  and  AXIN1,  respectively)  and  BMD 
(g/cm
2)  was  tested  using  an  Analysis  of  Covariance  (ANCOVA)  test.  This  technique  is  a 
general linear model which combines ANOVA and regression [119] to evaluate whether the 
population  means  of  a  dependent  variable  (i.e.  BMD)  are  equal  across  groups  of  a 
categorical independent variable (i.e. CNV genotype groups), while statistically controlling 
for the effects of other continuous variables that are not of primary interest (i.e. covariates) 
[119]. The ANCOVA test tested the hypothesis that there was no difference in mean BMD 
between the different CNV genotype groups, which was rejected if the p-value was less than 
the 0.05 significance level, indicating that there was evidence of a statistically significant  
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association between CNV, BMD, and covariates. Conversely, if the p-value was greater than 
the  0.05  significance  level,  the null  hypothesis  of equal  means  was not  rejected,  which 
would indicate that there was no evidence of a statistically significant association between 
CNV, BMD, and covariates. 
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Chapter 3: Analysis of ESR1 CNV and BMD 
    
60 
 
3.1 Introduction 
The oestrogen receptor 1 (ESR1) gene is one of the most extensively studied candidate 
genes for involvement in the regulation of bone. Several common genetic variants in the 
ESR1 gene have been described and are widely anticipated to contribute to phenotypic 
diversity of bone traits. For example, previous studies have identified three polymorphic 
sites in the 5’ end of the gene: a (TA)n variable number tandem repeat (VNTR) located 
approximately 1kb upstream of exon 1, and the PvuII and XbaI restriction fragment length 
polymorphisms (RFLPs) in intron 1, about 400 bp upstream of exon 2 [49]. Associations of 
these polymorphisms with bone traits have been reported, but results have been largely 
inconsistent between studies [49]. Nonetheless, several large-scale analysis projects firmly 
implicate genetic variations of ESR1 with BMD, thereby providing insights into the potential 
functional role that ESR1 plays in bone regulation. For example, a meta-analysis of five 
GWAS of BMD in 19,195 subjects (including 14,277 women of European descent) identified 
a total of 54 SNPs in intron 1 of ESR1 in statistically significant association with BMD, of 
which 36 SNPs were associated with lumbar spine BMD (lowest p value: 6.1 x 10
-11) and the 
remaining 18 SNPs were associated with femoral neck BMD (lowest p value: 3.0 x 10
-8) [98]. 
Moreover, these findings are comparable to those of similar studies [19; 121]. In view of 
this, there appears to be sufficient evidence to suggest that ESR1 may play an important 
role in bone regulation at multiple skeletal sites; however, the accurate elucidation of this 
depends on the biological plausibility. 
According to the UCSC Genome Browser, the ESR1 gene is 412,778 bp in length and is 
located on the cytoband 6q25.1c. It encodes the oestrogen receptor isoform, oestrogen 
receptor-α,  which  is  a  ligand-activated  transcription  factor  expressed  in  bone  marrow- 
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derived cells [122], such as osteoclasts, osteoblasts, osteocytes (a final differentiated cell 
type  of  the  osteoblast  lineage),  and  bone  marrow  stromal  cells  [6].  Previous  studies 
highlight a role for ESR1 as a mediator for the response of target cells to the effects of the 
reproductive steroid hormone, oestrogen [19]. In brief, being a typical steroid hormone, 
oestrogen can elicit a cellular response via direct and indirect regulation of gene expression. 
Direct regulation of gene expression involves the diffusion of oestrogen through the cellular 
membrane, where it binds to and activates its intracellular receptor, which then interacts 
with  the  hormone-response  and  regulatory  elements  of  oestrogen-responsive  genes, 
thereby initiating their transcription [123]. Indirect regulation of gene expression involves 
oestrogen binding to either steroid or non-steroid receptors, which induces kinase signalling 
pathways [124]. In view of this, it can be reasonably assumed that ESR1 may regulate the 
transcription of genes relevant to bone regulation, in response to oestrogen. 
It is well documented that oestrogen is essential for healthy bone turnover. Like the other 
reproductive  steroid  hormones,  it  is  a  key  regulator  of  osteoblast  differentiation  [125]. 
Although  oestrogen  has  been  shown  to  up-regulate  the  expression  of  osteoblastogenic 
markers in mesenchymal stem cells (MSCs) (i.e. RUNX2, ALPL, and COL1) [126] and promote 
the deposition of new bone, extensive clinical research indicates that the main effect of 
oestrogen on the promotion of bone formation actually lies in its inhibition of osteoclast 
differentiation [5; 127]. Therefore, oestrogen essentially promotes the protection against 
bone loss. For example, a study conducted by Bord et al in 2003 documented that human 
osteoblasts respond to low dose oestrogen treatment with the repression of RANKL, whilst 
maintaining the expression of the decoy ligand, OPG [128]. This suggests that oestrogen 
may inhibit RANKL from binding to RANK on osteoclast precursors by promoting down- 
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regulation of RANKL and up-regulation of OPG, which inhibits the activation of osteoclasts, 
thereby protecting against bone loss. Moreover, evidence that oestrogen also modulates 
cytokines (i.e. IL-6, IL-1, and TNF-α) and growth factors (i.e. TGF-β), coupled with evidence 
that these factors are potential mediators of osteoclast differentiation [129], even further 
highlights the critical role that oestrogen plays in bone regulation. 
Previous  studies  have  firmly  demonstrated  that  oestrogen  has  positive  effects  on  bone 
regulation, including bone turnover, acquisition of peak bone mass, and inhibition of bone 
loss [130]. In view of this, it appears reasonable to assume that oestrogen protects against 
osteoporosis. There are several lines of evidence supporting the role of oestrogen deficiency 
in osteoporosis. For example, postmenopausal women, whose oestrogen levels naturally 
decline,  are  known  to be  at the highest  risk  of  developing  the  disease  [19].  Moreover, 
women experience accelerated bone loss at a rate of 3 to 5% per year during menopause 
[25], which studies attribute to accelerated bone remodelling, as indicated by an increase in 
the levels of biological markers related to bone resorption and formation [5]. Consistent 
with this, oestrogen replacement in early menopausal women has been shown to decrease 
the  risk  of  osteoporotic  fractures  [49].  Therefore,  there  is  strong  evidence  implicating 
oestrogen deficiency with osteoporosis. 
In  view  of  existing  evidence  highlighting  the  activity  of  the  ESR1  gene,  the  oestrogen 
receptor-α, and oestrogen, it appears reasonable to assume that the normal, human diploid 
wild-type expression of ESR1 encodes a functional oestrogen receptor which mediates the 
response of target cells to oestrogen, thereby producing a phenotype which is consistent 
with healthy bone maintenance (i.e. high BMD and low fracture risk). Therefore, a loss or 
gain of ESR1 sequence in relation to ESR1 CNV may consequently cause a loss-of-function or  
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gain-of-function mutation,  respectively,  which may  disrupt the transcriptional  control of 
ESR1 or other genes. For example, a loss-of-function mutation in relation to ESR1 CNV may 
encode an altered oestrogen receptor-α which is no longer responsive to oestrogen and 
therefore does not offer protection against bone loss, thereby producing a phenotype which 
is consistent with an increased risk of osteoporosis. Conversely, a gain-of-function mutation 
in relation to ESR1 CNV may encode an altered receptor which enhances the protection 
against bone loss or may even have long-range positional effects on the transcriptional 
control  of  other  genes  which  have  completely  different  functional  roles  all  together. 
Nonetheless, the exact functional roles of both ESR1 and CNV remain to be fully elucidated 
and therefore gains and losses of function in relation to ESR1 CNV are currently difficult to 
interpret. 
According to the DGV, there are several known CNVs for the ESR1 gene. The ESR1 CNV 
identified as Variant_4512 was analysed in this study. Variant_4512 is a genomic sequence 
222,242 bp in length and constitutes a gain in ESR1 CN [131]. It was previously discovered by 
Wong  et  al  in  2007  using  the  bacterial  artificial  chromosome  (BAC)  array  CGH  analysis 
method [131]. It was selected for analysis in this current study based on criteria outlined in 
Section 2.2.1, but also because it encompasses the 5’ end of ESR1, where the promoter 
sequence  and  regulatory  elements  are  expected  to  be  located  [130],  which  therefore 
implicates  gene  expression.  Furthermore,  several  genetic  variations  of  the  ESR1  mRNA 
transcript, such as those located in the 5’ end, have already been implicated in association 
with phenotypes related to the risk of osteoporosis, such as BMD [49]. According to the 
UCSC Genome Browser, and highlighted in Figure 3, Variant_4512 does not encompass the  
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entirety of ESR1. Instead, it starts 51,847 bp upstream and then ends 360,931 bp into the 
gene. 
Figure 3: Genomic Location of ESR1 CNV Variant_4512 in Relation to ESR1 and C6orf97 
 
 
Interestingly, as indicated in Figure 3, it starts in close proximity to an open reading frame 
(ORF)  known  as  C6orf97.  This  genomic  region  is  currently  of  unknown  expression  and 
function, but GWAS have identified that several SNPs relevant to BMD are located either 
within or close to it [132]. Moreover, previous studies have shown that the majority of 
genes associated with CNV are not even located within the identified region of genetic 
variation [84]. Therefore, it appears reasonable to hypothesise that the activities of ESR1 
and C6orf97 in relation to bone regulation may be linked. Variant_4512 may cause ESR1 to 
encode an altered product which exerts long-range positional effects on the expression of 
C6orf97, which may even turn out to be the primary genomic region associated with the risk 
of osteoporosis, but further clinical research would be required to accurately elucidate its 
C6orf97 
ESR1 CNV Variant_4512 
ESR1 mRNA  
Variations  
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role. Nonetheless, considering that several genetic variations in the 5’ end of ESR1 have 
already been implicated in bone regulation, Variant_4512 seemed an appropriate CNV for 
investigating the potential association between ESR1 CNV and osteoporosis. 
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3.2 Materials and Methods 
This study investigated the potential effect of two different CNVs on BMD, and although the 
CNVs  were  analysed  separately,  all  methods  were  applied  in exactly  the  same  manner, 
unless otherwise indicated. Therefore, in this thesis, the analyses of ESR1 CNV and AXIN1 
CNV are collectively described in a general methods section (Refer to Chapter 2: Materials 
and Methods). 
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3.3 Results 
3.3.1 Quality Control 
The first measure of quality control of the experimental data was that no TaqMan signals 
were detected for DNA amplification in the NTC wells of every 384-well qPCR reaction plate 
run. qPCR data were examined for consistency and confidence between the two technical 
replicates of every analysed sample using the mean, SD, and SE, of the FAM and VIC signal 
intensities on the CT scale. By criteria modified for this study (Refer to Section 2.2.5.1), 
normally distributed data were located less than 1.0 SD above or below the mean. The 
majority  of  analysed  samples  had  a  SD  below  1.0,  so  they  were  within  the  acceptable 
threshold, and were thus approved for statistical analysis. Higher SD tended to correlate 
with a higher degree of variability displayed by the VIC signals, which were generally more 
variable  than  the  FAM  signals.  Several  samples  had  a  SD  exceeding  1.0  and  they  were 
defined as having an ‘unconfirmed’ CN (even if both technical replicates had the same CN 
predicted  by  CopyCaller).  ‘Unconfirmed’  samples  were  subjected  to  a  second  round  of 
genotyping, which in turn yielded an acceptable SD. Therefore, it was reasonably accepted 
that the majority of qPCR data in this study were sufficiently reproducible and reliable for 
CN assignment by CopyCaller. 
CopyCaller results were then examined for consistency and confidence between the two 
technical replicates of every analysed sample. By criteria modified for this study (Refer to 
Section 2.2.5.1), a ‘confirmed’ CN was assigned to a sample if both replicates were assigned 
the  same  CN  and  it  also  matched  up  with  the  CN  yielded  when  replicate  data  were 
combined  to  represent  a  single  sample.  Although  CopyCaller  could  not  produce  a 
confidence  score  for  only  two  replicates,  the  proven  reproducibility  of  the  qPCR  data  
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validated  the  reliability  of  the  CopyCaller  results.  Moreover,  the  ‘confirmed’  CN  for  9 
subjects could be accurately validated based on consistency with their random biological 
replicate included in the sample set. From the first round of genotyping, 547 out of 623 
samples had both replicates assigned the same CN by CopyCaller with sufficient confidence, 
and were thus defined as having a ‘confirmed’ CN and approved for statistical analysis. The 
remaining 76 samples had a discrepancy in CN between their replicates. ESR1 CNV reagents 
were not limiting at this point, so samples did not need to be prioritised for the second 
round of genotyping (Refer to Section 2.2.5.2). Therefore, the entire 76 samples could be 
analysed by qPCR and CopyCaller again.  
From the second round of genotyping, 35 out of the 76 previously ‘unconfirmed’ samples 
went on to yield a ‘confirmed’ CN with sufficient confidence. However, the remaining 41 
samples had failed, yet again, to yield a consistent CN between all four replicates that had 
been  analysed  to  date.  By  criteria  modified  for  this  study  (Refer  to  Section  2.2.5.3),  a 
‘confirmed’  CN  was  assigned  to  a  sample  if  the  CN  call  predicted  by  CopyCaller,  when 
replicate data were combined to represent a single sample, had a confidence score greater 
than 7.0. From here, 22 more samples were assigned a ‘confirmed’ CN, yet 19 ‘unconfirmed’ 
samples  with  a  poor  confidence  score  still  remained.  Considering  that  a  third  round  of 
genotyping was unfeasible at this point due to limiting reagents and time constraints, it was 
conceded that these samples had failed their reactions and they were therefore completely 
eliminated from statistical analysis. 
3.3.2 CNV Genotype Frequency Distributions 
A total of 624 subjects from the GENOS (STH-H) cohort were genotyped for the ESR1 CNV 
Variant_4512. 19 subjects could not be assigned a ‘confirmed’ CNV genotype due to CN  
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discrepancy  between  technical  replicates  and  poor  confidence  scores,  and  were  thus 
removed from the  study  cohort  in  statistical  analysis.  604  subjects  could be  assigned a 
‘confirmed’ CNV genotype; of which, 3 subjects had CN1, 595 subjects had CN2, and 6 
subjects had CN3. The ‘confirmed’ ESR1 CNV genotype frequency distributions are shown in 
Table 14. 
Table 14: Summary of Confirmed ESR1 CNV Genotypes 
CNV Status  Number of Subjects 
CN1  3 
CN2  595 
CN3  6 
Total  604 
 
3.3.3 SPSS Tests of Normality 
3.3.3.1 ESR1 CNV and Raw BMD Measurements (g/cm
2) 
Table 15 shows the results of the Shapiro-Wilk test of normality for the ESR1 CNV genotypes 
and BMD (g/cm
2) phenotypes. Given the null hypothesis of normal distribution, which was 
rejected if the significance level was less than 0.05, the results indicated the following; 
lumbar spine data were normally distributed for CN1 (p = 0.134), CN2 (p = 0.065), and CN3 
(p = 0.814); total hip data were normally distributed for CN1 (p = 0.347) and CN3 (p = 0.879), 
but  were  not  normally  distributed  for  CN2  (p  =  0.033);  and,  femoral  neck  data  were 
normally  distributed  for  CN1  (p  =  0.169)  and  CN3  (p  =  0.076),  but  were  not  normally 
distributed  for  CN2  (p  =  <  0.001).  The  df  indicates  the  number  of  samples  that  were  
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analysed  for  a  given  CNV  genotype  and  BMD  phenotype.  Note  that  the  CNV  genotype 
frequencies are different from those that were initially confirmed (Refer to Section 3.3.2), 
considering that a substantial number of samples had to be omitted from statistical analysis 
due to missing phenotype data. 
Table 15: Shapiro-Wilk Test of Normality for ESR1 CNV and BMD (g/cm
2) 
ESR1  
CNV 
Genotype 
Lumbar Spine  
BMD (g/cm
2) 
Total Hip  
BMD (g/cm
2) 
Femoral Neck  
BMD (g/cm
2) 
df  Sig.  df  Sig.  df  Sig. 
CN1  3  0.134  3  0.347  3  0.169 
CN2  434  0.065  430  0.033  421  < 0.001 
CN3  5  0.814  5  0.879  4  0.076 
 
The results of the Shapiro-Wilk normality tests were further confirmed by visually screening 
Normal Q-Q Plots and Box Plots, of which selected examples are shown in Figures 4 and 5, 
respectively. The Normal Q-Q Plots highlighted where the observed BMD (g/cm
2) values 
deviated from the trend-line of expected values for a normally distributed dataset of each 
CNV genotype and hence did not display normal distribution (i.e. Figure 4.i: CN2 and BMD 
(g/cm
2) at the total hip); and conversely, where observed data were consistent with the 
expected trend-line and hence contributed to normal distribution (i.e. Figure 4.ii: CN3 and 
BMD (g/cm
2) at the lumbar spine). The Box Plots highlighted where obvious outliers may 
have skewed the distribution away from normality (i.e. Figure 5.ii: CN2 and BMD (g/cm
2) at 
the femoral neck); and conversely, where the box plot was fairly symmetrical, albeit slightly  
71 
 
skewed, thereby reasonably indicating a normally distributed dataset (i.e. Figures 5.i and 
5.iii: CN1 and CN3, and BMD (g/cm
2) at the femoral neck). 
Figure 4: Selected Examples of Normal Q-Q Plots for ESR1 CNV and BMD (g/cm
2) 
i. CN2 and BMD (g/cm
2) at the Femoral Neck 
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ii. CN3 and BMD (g/cm
2) at the Lumbar Spine 
 
 
Figure 5: Selected Examples of Box Plots for ESR1 CNV and BMD (g/cm
2) 
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3.3.3.2 ESR1 CNV and Age-Adjusted BMD Z-Scores 
Table 16 shows the results of the Shapiro-Wilk test of normality for the ESR1 CNV genotypes 
and BMDZ phenotypes. Given the null hypothesis of normal distribution, which was rejected 
if the significance level was less than 0.05, the results indicated the following; lumbar spine 
data were normally distributed for CN1 (p = 0.387) and CN3 (p = 0.058), but were not 
normally distributed for CN2 (p = < 0.001); total hip data were normally distributed for CN1 
(p = 0.921) and CN3 (p = 0.558), but were not normally distributed for CN2 (p = < 0.001); 
and, femoral neck data were normally distributed for CN1 (p = 0.906) and CN3 (p = 0.405), 
but were not normally distributed for CN2 (p = < 0.001). 
Table 16: Shapiro-Wilk Test of Normality for ESR1 CNV and BMDZ 
ESR1  
CNV 
Genotype 
Lumbar Spine  
BMDZ 
Total Hip  
BMDZ 
Femoral Neck  
BMDZ 
df  Sig.  df  Sig.  df  Sig. 
CN1  3  0.387  3  0.921  3  0.906 
CN2  434  < 0.001  430  < 0.001  421  < 0.001 
CN3  5  0.058  5  0.558  4  0.405 
 
The results of the Shapiro-Wilk normality tests were further confirmed by visually screening 
Normal Q-Q Plots and Box Plots, of which selected examples are shown in Figures 6 and 7, 
respectively. The Normal Q-Q Plots highlighted where the observed BMDZ values deviated 
from  the  trend-line  of  expected  values  for  a  normally  distributed  dataset  of  each  CNV 
genotype and hence did not display normal distribution (i.e. Figure 6.i: CN2 and BMDZ at the  
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total hip); and conversely, where observed data were consistent with the expected trend-
line and hence contributed to normal distribution (i.e. Figure 6.ii: CN3 and BMDZ at the total 
hip). The Box Plots highlighted where obvious outliers may have skewed the distribution 
away from normality (i.e. Figure 7.ii: CN2 and BMDZ at the femoral neck); and conversely, 
where the Box Plot was highly symmetrical and evenly spaced, thereby indicating a normally 
distributed dataset (Figure 7.i: CN1 and BMDZ at the femoral neck), and also where the Box 
Plot was fairly symmetrical, albeit slightly skewed, thereby reasonably indicating a normally 
distributed dataset (i.e. Figure 7.iii: CN3 and BMDZ at the femoral neck). 
Figure 6: Selected Examples of Normal Q-Q Plots for ESR1 CNV and BMDZ  
i. CN2 and BMDZ at the Total Hip 
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ii. CN3 and BMDZ at the Total Hip 
 
 
Figure 7: Selected Examples of Box Plots for ESR1 CNV and BMDZ 
 
  
76 
 
3.3.4 Association Analysis 
3.3.4.1 ESR1 CNV and Raw BMD Measurements (g/cm
2) 
Table 17 shows the results of the Levene’s Test for Homogeneity of Variances. Given the null 
hypothesis of equal error variances, which was rejected if the significance level was less 
than 0.05, the results indicated that the error variances of BMD (g/cm
2) at the lumbar spine 
(p = 0.924), total hip (p = 0.756) and femoral neck (p = 0.203) were equal across all three of 
the ESR1 CNV genotype groups and hence the assumption for the ANOVA test was met. 
Table 17: Levene’s Test for Homogeneity of Variances for ESR1 CNV and BMD (g/cm
2) 
BMD Phenotype  df Between Groups  df Within Groups  Sig. 
Lumbar Spine BMD (g/cm
2)  2  439  0.924 
Total Hip BMDZ (g/cm
2)  2  435  0.756 
Femoral Neck BMDZ (g/cm
2)  2  425  0.203 
 
Table 18 shows the results of the ANOVA test. Given the null hypothesis that the difference 
in mean BMD (g/cm
2) between the three CNV genotype groups is no greater than that due 
to normal variation of subjects’ characteristics, and error in their measurement, which was 
rejected if the significance level was less than 0.05, the results indicated that there was no 
evidence of statistically significant association between ESR1 CNV and BMD (g/cm
2) at the 
lumbar spine (p = 0.530), total hip (p = 0.929), or femoral neck (p = 0.257). 
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Table 18: ANOVA Test of Association for ESR1 CNV and BMD (g/cm
2) 
BMD Phenotype  df Between Groups  df Within Groups  Sig. 
Lumbar Spine BMD (g/cm
2)  2  439  0.530 
Total Hip BMDZ (g/cm
2)  2  435  0.929 
Femoral Neck BMD (g/cm
2)  2  425  0.257 
 
3.3.4.2 ESR1 CNV and Age-Adjusted BMD Z-Scores 
Table 19 shows the results of the Levene’s Test for Homogeneity of Variances. Given the null 
hypothesis of equal error variances, which was rejected if the significance level was less 
than 0.05, the results indicated that the error variances of BMDZ at the lumbar spine (p = 
0.896), total hip (p = 0.760) were equal across all three of the ESR1 CNV genotype groups 
and hence the assumption for the parametric ANOVA test was met. The results indicated 
that error variances of BMDZ at the femoral neck (p = 0.048) were not equal across all three 
of the ESR1 CNV genotype groups; however, the p value was approximately equal to the 
0.05 significance level, so it was reasonably assumed that the assumption for the parametric 
ANOVA test was met. 
Table 19: Levene’s Test for Homogeneity of Variances for ESR1 CNV and BMDZ  
BMD Phenotype  df Between Groups  df Within Groups  Sig. 
Lumbar Spine BMDZ  2  439  0.896 
Total Hip BMDZ  2  435  0.760 
Femoral Neck BMDZ  2  425  0.048 
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Table 20 shows the results of the ANOVA test. Given the null hypothesis that the difference 
in mean BMDZ between the three ESR1 CNV genotype groups is no greater than that due to 
normal variation of subjects’ characteristics, and error in their measurement, which was 
rejected if the significance level was less than 0.05, the results indicated that there was no 
evidence of statistically significant association between ESR1 CNV and BMDZ at the lumbar 
spine (p = 0.261), total hip (p = 0.915), or femoral neck (p = 0.111). 
Table 20: ANOVA Test of Association for ESR1 CNV and BMDZ 
BMD Phenotype  df Between Groups  df Within Groups  Sig. 
Lumbar Spine BMDZ  2  439  0.261 
Total Hip BMDZ  2  435  0.915 
Femoral Neck BMDZ  2  425  0.111 
 
3.3.4.3 Effect of Covariates on ESR1 CNV and BMD Measurements (g/cm
2) 
Table 21 shows the results of the Levene’s Test for Homogeneity of Variances. Given the null 
hypothesis of equal error variances, which was rejected if the significance level was less 
than 0.05, the results indicated that the error variances of BMD (g/cm
2) at the lumbar spine 
(p = 0.796), total hip (p = 0.851), and femoral neck (p = 0.070) were equal across all three of 
the ESR1 CNV genotype groups with the effect of the covariates height, weight, age, age
2, 
and BMI and hence the assumption for the ANOVA test was met. 
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Table  21:  Levene’s  Test  for  Homogeneity  of  Variances  of  ESR1  CNV  and  BMD  (g/cm
2), 
Controlled for Covariates 
BMD Phenotype  df Between Groups  df Within Groups  Sig. 
Lumbar Spine BMD (g/cm
2)  2  404  0.796 
Total Hip BMD (g/cm
2)  2  402  0.851 
Femoral Neck BMD (g/cm
2)  2  397  0.070 
 
Table 22 shows the results of the ANCOVA test. Given the null hypothesis that the difference 
in mean BMD (g/cm
2) between the three CNV genotype groups is no greater than that due 
to normal variation of subjects’ characteristics, and error in their measurement, which was 
rejected if the significance level was less than 0.05, the results indicated that there was no 
evidence of statistically significant association between ESR1 CNV and BMD (g/cm
2) at the 
lumbar spine (p = 0.171), total hip (p = 0.671), or femoral neck (p = 0.052), when controlled 
for the covariates; height, weight, age, age
2, and BMI. 
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Table  22:  ANCOVA  Test  of  Association  for  ESR1  CNV  and  BMD  (g/cm
2),  Controlled  for 
Covariates  
BMD  
Phenotype 
Lumbar Spine BMD 
(g/cm
2) 
Total Hip BMD 
(g/cm
2) 
Femoral Neck BMD 
(g/cm
2) 
Covariate  df  Sig.  df  Sig.  df  Sig. 
Height  1  0.303  1  0.904  1  0.119 
Weight  1  0.042  1  0.404  1  0.009 
Age  1  0.146  1  0.117  1  < 0.001 
Age
2  1  0.002  1  0.630  1  0.100 
BMI  1  0.121  1  0.994  1  0.070 
ESR1 CNV  2  0.171  2  0.671  2  0.052 
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3.4 Discussion 
This study investigated the potential effect of CNV in the pathogenesis of osteoporosis, with 
a CNV of the ESR1 gene being one of the two CNVs of interest. The ESR1 gene encoding the 
oestrogen receptor-α and mediating the response of target cells to oestrogen is a strong 
candidate for the genetic regulation of phenotypes related to the risk of osteoporosis, such 
as  bone  mass,  bone  remodelling,  and  postmenopausal  bone  loss.  In  previous  studies, 
several genetic variations located in intron 1 and the 5’ end of ESR1 have been described 
and  their  associations  with  BMD  have  been  reported,  but  results  have  been  largely 
inconsistent between studies [49; 98]. Nonetheless, there is still evidence supporting the 
potential association between genetic variation encompassing intron 1 and the 5’ end of 
ESR1 and the surrogate phenotype of osteoporosis, BMD. 
This study tested the potential effect of the ESR1 CNV Variant_4512 in relation to BMD at 
three common skeletal locations of osteoporotic fracture (i.e. lumbar spine, total hip, and 
femoral neck) in a family-based population cohort study of Caucasian women from Australia 
and  the  UK.  This  study  did  not  detect  any  statistically  significant  associations  between 
Variant_4512  and  BMD  (g/cm
2)  at  the  lumbar  spine,  total  hip,  or  femoral  neck,  in  the 
analysed subject cohort. Moreover, no associations were found between Variant_4512 and 
BMD after the BMD data were corrected for age (BMDZ) at the three skeletal locations in 
the cohort. Furthermore, no associations were found after testing the potential effect of 
covariates  (i.e.  age,  age
2,  height,  weight,  and  BMI)  on  the  relationship  between 
Variant_4512 and BMD (g/cm
2) at the three skeletal locations in the cohort. Despite the 
comprehensive lack of statistical significance, the level of association between Variant_4512 
and BMD at all skeletal sites in the cohort tended slightly more towards significance when  
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BMD  data  were  adjusted  for  age  (BMDZ).  However,  this  level  of  association  increased 
dramatically when controlled for covariates. Nonetheless, in this study of Caucasian women, 
the ESR1 CNV genotype had no statistically significant effect on the BMD phenotype. 
In  summary,  this  study  successfully  genotyped  ESR1  CNV  and  tested  for  its  potential 
association  with  BMD, but found  no  statistically  significant  association.  Previous  studies 
have indicated that the ESR1 gene mediates the response of bone marrow-derived cells to 
oestrogen [122] and it has been demonstrated that oestrogen protects against phenotypes 
related to osteoporosis, such as low BMD [130]. Moreover, previous studies have already 
implicated several genetic variations of ESR1 with BMD. Variant_4512 encompasses the 5’ 
end of the gene and constitutes a gain in ESR1 CN. In view of this, the regulators of gene 
expression would be expected to duplicate, thereby potentially enhancing the protective 
quality of ESR1 against low BMD. Therefore, the ESR1 CNV Variant_4512 was anticipated to 
have a more significant effect on BMD than was found in this study. Nonetheless, it appears 
that the presence of ESR1 CNV was successfully detected and quantitated in the analysed 
cohort, as indicated by the observation of three distinct CNV genotype groups, representing 
CN loss (CN1) and CN gain (CN3) from the expected wild-type CN in the human diploid 
genome (CN2). Therefore, the relationship between ESR1 CNV and BMD most likely has a 
confounding feature that has yet to be resolved. 
An interesting observation in this study was that the association between ESR1 CNV and 
BMD (g/cm
2) at the femoral neck increased dramatically and almost qualified as statistically 
significant when controlled for covariates (p = 0.052). It appears that this near-significant 
association was influenced by the extremely statistically significant associations between 
BMD  (g/cm
2)  at  the  femoral  neck,  and  age  (p  =  <  0.001)  and  weight  (p  =  0.009).  This  
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observation offers preliminary insights into the potential relationship between ESR1 CNV 
and  BMD.  Despite  the  lack  of  statistical  significance,  this  near-significant  association 
between ESR1 CNV and BMD, when the effects of covariates were tested, indicates that 
Variant_4512 may be susceptible to modification in an environmental-specific way, which 
may in turn influence its effect on BMD. Therefore, Variant_4512 may turn out to be a 
promising candidate for targeted intervention measures to prevent osteoporosis. However, 
further studies would be required to accurately elucidate this, and to determine whether 
the environmental variables are of direct interest, or if they are interacting or confounding 
variables. 
There have been no previous studies of ESR1 CNV and hence its clinical relevance to BMD or 
other phenotypes related to the risk of osteoporosis remains to be elucidated. Therefore, it 
would be impossible to accurately validate or refute the findings from this study without 
any  corroborating  evidence  from  previous  studies.  Nonetheless,  there  is  evidence  from 
previous studies implicating intron 1 and the 5’ end of the ESR1 gene with BMD [49; 98]. The 
ESR1  CNV  Variant_4512  encompasses  this  region  of  the  gene,  which  is  also  where  the 
promoter sequence and regulatory elements are expected to be located and control gene 
expression, which is the fundamental level at which genotype gives rise to phenotype [67]. 
Therefore, despite the lack of significant findings in this study, the ESR1 CNV Variant_4512 
still remains a promising candidate for involvement in BMD and the risk of osteoporosis.
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Chapter 4: Analysis of AXIN1 CNV and BMD    
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4.1 Introduction 
The AXIN1 gene is a recognised candidate gene for involvement in the regulation of bone, 
albeit not as extensively studied or as fully understood as the ESR1 gene. Nonetheless, 
several large-scale analysis projects firmly implicate a genetic variation of the AXIN1 gene 
with BMD, thereby providing insights into the potential functional role that AXIN1 plays in 
bone  regulation.  A  meta-analysis  of  seventeen  GWAS  of  BMD  in  32,961  subjects  of 
European and East Asian descent identified a SNP (rs9921222) within intron 2 of AXIN1 in 
statistically significant association with BMD at the lumbar spine (p = 2.5 x 10
-7) and at the 
femoral neck (p = 2.2 x 10
-8) [133]. Furthermore, previous studies have firmly implicated 
AXIN1  with  numerous  common  complex  diseases,  including  carcinomas  and 
medulloblastomas [134]. In view of this, there appears to be reasonable evidence to suggest 
that AXIN1 may play an important role in bone regulation at multiple skeletal sites and may 
be  implicated  with  the  common  complex  disease,  osteoporosis.  However,  the  accurate 
elucidation of this depends on the biological plausibility. 
According to the UCSC Genome Browser, the  AXIN1 gene is 65,024 bp in length and is 
located on the cytoband 16b13.3f. It encodes an isoform of the cytoplasmic protein Axin, 
Axin-1 [135], which has interaction sites for numerous proteins that are involved in the Wnt 
signalling pathway, including  β-catenin, APC, GSK, TGF-β, casein kinase I, DvI, and the LRP 
receptors [135]. Furthermore, previous studies have demonstrated that Axin-1, combined 
with  the  other  Axin  isoform,  Axin-2,  acts  as  the  scaffold  for  a  protein  complex  which 
negatively regulates the canonical Wnt signalling pathway [135; 136]. In brief, this pathway 
involves  the  binding  of  Wnt  proteins  to  cell-surface  receptors  of  the  soluble  Fz-related 
family of proteins, which activates the Dvl family of proteins, resulting in the inhibition of  
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the protein complex for which Axin is the scaffold, which also includes APC, GSK-3, and β-
catenin [135; 136; 137]. As a result, Axin is recruited to the LRP receptor complex where 
interaction with DvI leads to Axin degradation and the release of active β-catenin [135; 136; 
137].  This  protein  subsequently  translocates  to  the  nucleus,  where  it  associates  with 
TCF/LEF  transcription  factors  and  regulates  the  transcription  of  genes  which  evidence 
suggests are involved in the regulation of cell growth and adhesion between cells [138]. In 
the  absence  of  Wnt  proteins,  Dvl  does  not  recruit  Axin  for  degradation,  and  thus  the 
Axin/APC/GSK-3/β-catenin protein complex remains intact and active [135]. As a result, β-
catenin is phosphorylated by GSK-3, which results in its ubiquitination by E3 ubiquitin ligase 
with  subsequent  degradation  in  the  26S  proteasome  [135].  Therefore,  Axin1  and  its 
homolog Axin2 appear to be negative regulators of the canonical Wnt signalling pathway. As 
previously stated, Wnt signal transduction is one of the key regulators of bone turnover and 
in most cases Wnt proteins promote bone growth [19]. In view of this, it can be reasonably 
assumed that AXIN1 may regulate the transcription of genes relevant to bone regulation 
and most likely inhibits the promotion of bone growth. 
In view of existing evidence highlighting the activity of the AXIN1 gene and the canonical 
Wnt signalling pathway, it appears reasonable to assume that the normal, human diploid 
wild-type expression of AXIN1 encodes a functional cytoplasmic protein which inhibits Wnt 
signal transduction, and in turn produces a phenotype which is consistent with unhealthy 
bone maintenance (i.e. low BMD and high fracture risk). Therefore, a loss or gain of AXIN1 
sequence in relation to AXIN1 CNV may consequently cause a loss-of-function or gain-of-
function mutation, respectively, which may disrupt the transcriptional control of AXIN1 or 
other genes. For example, a loss-of-function mutation in relation to AXIN1 CNV may encode  
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an altered Axin1 cytoplasmic protein which no longer inhibits the canonical Wnt signalling 
pathway  through  the  degradation  of  β-catenin  and  may  therefore  result  in  the 
overexpression of β-catenin. Previous studies have investigated the functional significance 
of β-catenin overexpression and evidence suggests that it reduces the promoter activity of 
the RANKL protein [139]. Moreover, it is the overexpression of RANKL and the subsequent 
enhanced  activation  of  osteoclasts  which  is  firmly  implicated  in  bone  disease  [18;  19]. 
Therefore, it appears reasonable to hypothesise that a loss-of-function mutation in relation 
to AXIN1 CNV may in fact offer some kind of protection against bone disease by inhibiting 
bone  loss,  thereby  producing  a  phenotype  which  is  consistent  with  a  decreased  risk  of 
osteoporosis.  
According to the DGV, there are several known CNVs for the AXIN1 gene. The AXIN CNV 
identified as Variant_4912 was analysed in this study. Variant_4912 is a genomic sequence 
192,851 bp in length and constitutes a loss in AXIN1 CN [131]. It was previously discovered 
by Wong et al in 2007 using the BAC array CGH analysis method [131]. It was selected for 
analysis in this current study based on criteria outlined in section 2.2.1.2, but also because it 
encompasses  the  entirety  of  AXIN1,  implicating  the  promoter  sequence  and  regulatory 
elements, which therefore implicates gene expression. Furthermore, a genetic variation in 
intron 2 of AXIN1 [133] and several genetic variations of other genes involved in Wnt signal 
transduction have already been implicated in association with phenotypes related to the 
risk of osteoporosis [19]. According to the UCSC Genome Browser, and highlighted in Figure 
8, Variant_4912 starts 4065 bp upstream of the AXIN1 gene and then ends 123,762 bp 
downstream of the gene.  
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Figure 8: Genomic Location of AXIN1 CNV Variant_4912 in Relation to AXIN1 and RAB11FIP3 
 
 
In view of this, as indicated in Figure 8, it encompasses a large section of genomic sequence 
that is not AXIN1. Interestingly, it encompasses the 5’ end of the RAB11 family interacting 
protein 3 (class II) (RAB11FIP3) gene, potentially implicating the promoter sequence and 
regulatory elements, which therefore potentially implicates gene expression. According to 
the UCSC Genome Browser, the 5’ end of the RAB11FIP3 gene contains active regulatory 
elements and studies have demonstrated that its molecular function involves calcium ion 
binding [122]. Therefore, it appears reasonable to hypothesise that the activities of AXIN1 
and RAB11FIP3 in relation to bone regulation may be linked. Variant_4912 may cause one 
gene  to  encode  an  altered  product  which  exerts  long-range  positional  effects  on  the 
expression of the other gene. Considering the importance of the calcium hormone in bone 
regulation [5], RAB11FIP3 may even turn out to be the primary gene associated with the risk 
of osteoporosis, but further clinical research would be required to accurately elucidate its 
role.  Nonetheless,  considering that  a  SNP  (rs9921222)  located  in  intron  2  of  AXIN1  has 
RAB11FIP3 
AXIN1 CNV Variant_4912 
AXIN1 mRNA  
Variations  
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already been implicated in bone regulation, Variant_4912 seemed an appropriate CNV for 
investigating the potential association between AXIN1 CNV and osteoporosis. 
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4.2 Materials and Methods 
This study investigated the potential effect of two different CNVs on BMD, and although the 
CNVs  were  analysed  separately,  all  methods  were  applied  in exactly  the  same  manner, 
unless otherwise indicated. Therefore, in this thesis, the analyses of ESR1 CNV and AXIN1 
CNV are collectively described in a general methods section (Refer to Chapter 2: Materials 
and Methods). 
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4.3 Results 
4.3.1 Quality Control 
The first measure of quality control of the experimental data was that no TaqMan signals 
were detected for DNA amplification in the NTC wells of every 384-well qPCR reaction plate 
run. qPCR data were examined for consistency and confidence between the two technical 
replicates of every analysed sample using the mean, SD, and SE, of the FAM and VIC signal 
intensities on the CT scale. By criteria modified for this study (Refer to Section 2.2.5.1), 
normally distributed data were located less than 1.0 SD above or below the mean. The 
majority  of  analysed  samples  had  a  SD  below  1.0,  so  they  were  within  the  acceptable 
threshold, and thus were approved for statistical analysis. Higher SD tended to correlate 
with a higher degree of variability displayed by the VIC signals, which were generally more 
variable  than  the  FAM  signals.  Several  samples  had  a  SD  exceeding  1.0  and  they  were 
defined as having an ‘unconfirmed’ CN (even if both technical replicates had the same CN 
predicted  by  CopyCaller).  ‘Unconfirmed’  samples  were  subjected  to  a  second  round  of 
genotyping, which in turn yielded an acceptable SD. Therefore, it was reasonably accepted 
that the majority of qPCR data in this study were sufficiently reproducible and reliable for 
CN assignment by CopyCaller.  
CopyCaller results were then examined for consistency and confidence between the two 
technical replicates of every analysed sample. By criteria modified for this study (Refer to 
Section 2.2.5.1), a ‘confirmed’ CN was assigned to a sample if both replicates were assigned 
the  same  CN  and  it  also  matched  up  with  the  CN  yielded  when  replicate  data  were 
combined  to  represent  a  single  sample.  Although  CopyCaller  could  not  produce  a 
confidence  score  for  only  two  replicates,  the  proven  reproducibility  of  the  qPCR  data  
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validated  the  reliability  of  the  CopyCaller  results.  Moreover,  the  ‘confirmed’  CN  for  9 
subjects could be accurately validated based on consistency with their random biological 
replicate included in the sample set. From the first round of genotyping, 441 out of 623 
samples had both replicates assigned the same CN by CopyCaller with sufficient confidence, 
and were thus defined as having a ‘confirmed’ CN and approved for statistical analysis. The 
remaining  182  samples  had  a  discrepancy  in  CN  between  their  replicates.  AXIN1  CNV 
reagents were limiting at this point, so samples had to be prioritised for the second round of 
genotyping based on certain criteria (Refer to Section 2.2.5.2). As a result, 78 samples which 
had yielded an ‘undetermined’ CN for either replicate from the first round of genotyping 
were  completely  eliminated  from  further  analysis.  Moreover,  another  2  samples  were 
omitted  due  to  insufficient  stock  volumes  of  gDNA.  Therefore,  104  samples  could  be 
analysed by qPCR and CopyCaller again.  
From  the  second  round  of  genotyping,  48  out  of  the  104  prioritised,  previously 
‘unconfirmed’  samples  went  on  to  yield  a  ‘confirmed’  CN  with  sufficient  confidence. 
However, the remaining 56 samples had failed, yet again, to yield a consistent CN between 
all four replicates that had been analysed to date. By criteria modified for this study (Refer 
to Section 2.2.5.3), a ‘confirmed’ CN was assigned to a sample if the CN call predicted by 
CopyCaller,  when  replicate  data  were  combined  to  represent  a  single  sample,  had  a 
confidence  score  greater  than  7.0.  From  here,  31  further  samples  were  assigned  a 
‘confirmed’ CN, yet 25 ‘unconfirmed’ samples with a poor confidence score still remained. 
Considering that a third round of genotyping was unfeasible at this point due to limiting 
reagents and time constraints, it was conceded that these samples had failed their reactions 
and they were therefore completely eliminated from statistical analysis.  
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4.3.2 CNV Genotype Frequency Distributions 
A total of 624 subjects from the GENOS (STH-H) cohort were genotyped for the AXIN1 CNV, 
Variant_4912. 104 subjects could not be assigned a ‘confirmed’ CNV genotype due to CN 
discrepancy  between  technical  replicates  and  poor  confidence  scores,  and  were  thus 
removed from the  study  cohort  in  statistical  analysis.  520  subjects  could be  assigned a 
‘confirmed’ CNV genotype; of which, 1 subjects had CN1, 506 subjects had CN2, and 13 
subjects had CN3. The ‘confirmed’ AXIN1 CNV genotype frequency distributions are shown 
in Table 23. 
Table 23: Summary of Confirmed AXIN1 Variant_4912 CNV Genotypes 
CNV Status  Number of Subjects 
CN1  1 
CN2  506 
CN3  13 
Total  520 
 
4.3.3 SPSS Tests of Normality 
4.3.3.1 AXIN1 and Raw BMD Measurements (g/cm
2) 
Table  24  shows  the  results  of  the  Shapiro-Wilk  test  of  normality  for  the  AXIN1  CNV 
genotypes and BMD (g/cm
2) phenotypes. Given the null hypothesis of normal distribution, 
which was rejected if the significance level was less than 0.05, the results indicated the 
following; lumbar spine data were normally distributed for CN2 (p = 0.112) and CN3 (p = 
0.309); total hip data were not normally distributed for CN2 (p = 0.011) or CN3 (p = 0.0.21);  
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and, femoral neck  data  were  not normally distributed  for  CN2  (p  = <  0.001),  but  were 
normally distributed for CN3 (p = 0.464). The df indicates the number of samples that were 
analysed  for  a  given  CNV  genotype  and  BMD  phenotype.  Note  that  the  CNV  genotype 
distributions are different from those that were initially ‘confirmed’ (Refer to Section 4.3.2), 
considering that a substantial number of samples had to be omitted from statistical analysis 
due to missing phenotype data. 
Table 24: Shapiro-Wilk Test of Normality for AXIN1 CNV and BMD (g/cm
2) 
AXIN1 
CNV 
Genotype 
Lumbar Spine  
BMD (g/cm
2) 
Total Hip  
BMD (g/cm
2) 
Femoral Neck  
BMD (g/cm
2) 
df  Sig.  df  Sig.  df  Sig. 
CN2  345  0.112  342  0.011  333  0.000 
CN3  9  0.309  9  0.021  9  0.464 
 
The results of the Shapiro-Wilk normality tests were further confirmed by visually screening 
Normal Q-Q Plots and Box Plots, of which selected examples are shown in Figures 9 and 10, 
respectively. The Normal Q-Q Plots highlighted where the observed BMD (g/cm
2) values 
deviated from the trend-line of expected values for a normally distributed dataset of each 
CNV genotype and hence did not display normal distribution (i.e. Figure 9.i: CN3 and BMD 
(g/cm
2) at the lumbar spine); and conversely, where observed data were consistent with the 
expected trend-line and hence contributed to normal distribution (i.e. Figure 9.ii: CN3 and 
BMD (g/cm
2) at the femoral neck). The Box Plots highlighted where obvious outliers may 
have skewed the distribution away from normality (i.e. Figure 10.i: CN2 and BMD (g/cm
2) at 
the femoral neck): and conversely, where the box plot was fairly symmetrical, albeit slightly  
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skewed, thereby reasonably indicating a normally distributed dataset (i.e. Figure 10.ii: CN3 
and BMD (g/cm
2) at the femoral neck) 
Figure 9: Selected Examples of Normal Q-Q Plots for AXIN1 CNV and BMD (g/cm
2) 
i. CN3 and BMD (g/cm
2) at the Lumbar Spine 
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ii. CN3 and BMD (g/cm
2) at the Femoral Neck 
 
 
Figure 10: Selected Examples of Box Plots for AXIN1 CNV and BMD (g/cm
2) 
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4.3.3.2 Age-Adjusted BMD Z-Scores 
Table  27  shows  the  results  of  the  Shapiro-Wilk  test  of  normality  for  the  AXIN1  CNV 
genotypes and BMDZ phenotypes. Given the null hypothesis of normal distribution, which 
was rejected if the significance level was less than 0.05, the results indicated the following; 
lumbar spine data were not normally distributed for CN2 (p = < 0.001), but were normally 
distributed for CN3 (p = 0.166); total hip data were not normally distributed for CN2 (p = < 
0.001) or CN3 (p = 0.012); and, femoral neck data were not normally distributed for CN1 (p = 
< 0.001), but were normally distributed for CN3 (p = 0.386). The df indicates the number of 
samples that were analysed for a given CNV genotype and BMDZ phenotype. Note that the 
CNV genotype distributions are different from those that were initially ‘confirmed’ (Refer to 
Section 3.2.2), considering that a substantial number of samples had to be omitted from 
statistical analysis due to missing phenotype data. 
Table 27: Shapiro-Wilk Test of Normality for AXIN1 CNV and BMDZ 
AXIN1 
CNV 
Genotype 
Lumbar Spine  
BMDZ 
Total Hip  
BMDZ 
Femoral Neck  
BMDZ 
df  Sig.  df  Sig.  df  Sig. 
CN2  345  0.000  342  0.000  333  0.000 
CN3  9  0.166  9  0.012  9  0.386 
 
The results of the Shapiro-Wilk normality tests were further confirmed by visually screening 
Normal Q-Q Plots and Box Plots, of which selected examples are shown in Figures 11 and 12, 
respectively. The Normal Q-Q Plots highlighted where the observed BMDZ values deviated  
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from  the  trend-line  of  expected  values  for  a  normally  distributed  dataset  of  each  CNV 
genotype and hence did not display normal distribution (i.e. Figure 11.i: CN2 and BMDZ at 
the total hip); and conversely, where observed data were consistent with the expected 
trend-line and hence contributed to normal distribution (i.e. Figure 11.ii: CN3 and BMDZ at 
the  total  hip).  The  Box  Plots  highlighted  where  obvious  outliers  may  have  skewed  the 
distribution away from normality (i.e. Figure 12.i: CN2 and BMDZ at the femoral neck); and 
conversely,  where  the  box  plot  was  fairly  symmetrical,  albeit  slightly  skewed,  thereby 
reasonably indicating a normally distributed dataset (i.e. Figure 12.ii: CN3 and BMDZ at the 
femoral neck). 
Figure 11: Selected Examples of Normal Q-Q Plots for AXIN1 CNV and BMDZ  
i. CN2 and BMDZ at the Total Hip 
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ii. CN3 and BMDZ at the Total Hip 
 
 
Figure 12: Selected Examples of Box Plots for AXIN1 CNV and BMDZ 
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4.3.4 Association Analysis 
4.3.4.1 AXIN1 CNV and Raw BMD Measurements (g/cm
2) 
Table 28 shows the results of the Levene’s Test for Homogeneity of Variances. Given the null 
hypothesis of equal error variances, which was rejected if the significance level was less 
than 0.05, the results indicated that the error variances of BMD (g/cm
2) at the lumbar spine 
(p = 0.507), total hip (p = 0.823) and femoral neck (p = 0.578), were equal across the two 
AXIN1 CNV genotype groups and hence the assumption for the parametric Independent-
Sample T-Test was met. 
Table 28: Levene’s Test for Homogeneity of Variances for AXIN1 CNV and BMD (g/cm
2) 
BMD Phenotype  df Between Groups  df Within Groups  Sig. 
Lumbar Spine BMD (g/cm
2)  1  352  0.507 
Total Hip BMD (g/cm
2)  1  349  0.823 
Femoral Neck BMD (g/cm
2)  1  340  0.578 
 
Table 29 shows the results of the Independent-Sample T-test. Given the null hypothesis that 
the difference in mean BMD (g/cm
2) between the two AXIN1 CNV genotype groups is no 
greater than that due to normal variation of subjects’ characteristics, and error in their 
measurement, which was rejected if the significance level was less than 0.05, the results 
indicated that there was no evidence of statistically significant association between AXIN1 
CNV and BMD (g/cm
2) at the lumbar spine (p = 0.249), total hip (p = 0.900), or femoral neck 
(p = 0.657). 
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Table 29: Independent-Sample T-Test of Association for AXIN1 CNV and BMD (g/cm
2) 
BMD Phenotype  df  Sig. 
Lumbar Spine BMD (g/cm
2)  352  0.249 
Total Hip BMD (g/cm
2)  349  0.900 
Femoral Neck BMDZ (g/cm
2)  340  0.657 
 
4.3.4.2 AXIN1 CNV and Age-Adjusted BMD Z-Scores 
Table 30 shows the results of the Levene’s Test for Homogeneity of Variances. Given the null 
hypothesis of equal error variances, which was rejected if the significance level was less 
than 0.05, the results indicated that the error variances of BMDZ at the lumbar spine (p = 
0.766), total hip (p = 0.662), and femoral neck (p = 0.534), were equal across the two AXIN1 
CNV genotype groups and hence the assumption for the t-test test was met. 
Table 30: Levene’s Test for Homogeneity of Variances for AXIN1 CNV and BMDZ  
BMD Phenotype  df Between Groups  df Within Groups  Sig. 
Lumbar Spine BMDZ  1  352  0.766 
Total Hip BMDZ  1  349  0.662 
Femoral Neck BMDZ  1  340  0.534 
 
Table 31 shows the results of the Independent-Sample T-Test. Given the null hypothesis that 
the difference in mean BMDZ between the two AXIN1 CNV genotype groups is no greater 
than  that  due  to  normal  variation  of  subjects’  characteristics,  and  error  in  their 
measurement, which was rejected if the significance level was less than 0.05, the results  
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indicated that there was no evidence of statistically significant association between AXIN1 
CNV and BMDZ at the lumbar spine (p = 0.226), total hip (p = 0.945) or femoral neck (p = 
0.667). 
Table 31: Independent-Sample T-Test of Test of Association for AXIN1 CNV and BMDZ 
BMD Phenotype  df  Sig. 
Lumbar Spine BMDZ  352  0.226 
Total Hip BMDZ  349  0.945 
Femoral Neck BMDZ  340  0.667 
 
4.3.4.3 Effect of Covariates on AXIN1 CNV and BMD Measurements (g/cm
2) 
Table 32 shows the results of the Levene’s Test for Homogeneity of Variances. Given the null 
hypothesis of equal error variances, which was rejected if the significance level was less 
than 0.05, the results indicated that the error variances of BMD (g/cm
2) at the lumbar spine 
(p = 0.952), total hip (p = 0.686) and femoral neck (p = 0.821) were equal across all three of 
the AXIN1 CNV genotype groups with the effect of the covariates height, weight, age, age
2 
and BMI and hence the assumption for the ANOVA test was met. 
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Table 32: Levene’s Test for Homogeneity of Variances for AXIN1 CNV and BMD (g/cm
2), 
Controlled for Covariates 
BMD Phenotype  df Between Groups  df Within Groups  Sig. 
Lumbar Spine BMD (g/cm
2)  1  324  0.952 
Total Hip BMD (g/cm
2)  1  323  0.686 
Femoral Neck BMD (g/cm
2)  1  319  0.821 
 
Table 33 shows the results of the ANCOVA test. Given the null hypothesis that the difference 
in  mean  BMD  (g/cm
2)  between  the  two  AXIN1  CNV  genotype  groups,  controlling  for 
covariates, is no greater than that due to normal variation of subjects’ characteristics, and 
error in their measurement, which was rejected if the significance level was less than 0.05, 
the  results  indicated  that  there  was  no  evidence  of  statistically  significant  association 
between AXIN1 CNV and BMD (g/cm
2) at the lumbar spine (p = 0.258), total hip (p = 0.709), 
or femoral neck (p = 0.916) with the effect of the covariates height, weight, age, age
2, and 
BMI. 
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Table  33:  ANCOVA  Test  of  Association  for  AXIN1  CNV  and  BMD  (g/cm
2),  Controlled for 
Covariates 
BMD  
Phenotype 
Lumbar Spine BMD 
(g/cm
2) 
Total Hip BMD 
(g/cm
2) 
Femoral Neck BMD 
(g/cm
2) 
Covariate  df  Sig.  df  Sig.  df  Sig. 
Height  1  0.105  1  0.894  1  0.048 
Weight  1  0.010  1  0.269  1  0.002 
Age  1  0.583  1  0.047  1  0.000 
Age
2  1  0.043  1  0.875  1  0.009 
BMI  1  0.026  1  0.753  1  0.021 
AXIN1 CNV  1  0.258  1  0.709  1  0.916 
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4.4 Discussion 
This study investigated the potential effect of CNV in the pathogenesis of osteoporosis, with 
a CNV of the AXIN1 gene being one of the two CNVs of interest. The AXIN1 gene encoding 
the Axin-1 protein and inhibiting the Wnt signalling pathway is a recognised candidate for 
the genetic regulation of phenotypes related to the risk of osteoporosis, such as BMD, bone 
mass, and bone remodelling. In previous studies, a SNP (rs9921222) located in intron 2 of 
AXIN1 has been described and its associations with BMD have been reported, but the exact 
functional  role  of  AXIN1  and hence the  consequence  of  AXIN1  CNV has  yet  to be fully 
elucidated. Nonetheless, there is still evidence supporting the association between genetic 
variation of AXIN1 and the surrogate phenotype of osteoporosis, BMD. 
The presence of AXIN1 CNV in the analysed cohort was indicated by the observation of 
three distinct CNV genotype groups, representing CN loss (CN1) and CN gain (CN3) from the 
expected  wild-type  CN  in  the  human  diploid  genome  (CN2).  The  discovery  study  that 
originally detected the AXIN1 CNV Variant_4912 reported that it constitutes a loss in AXIN1 
CN [131]. The only subject confirmed for the presence of CN loss in this current study had to 
be omitted from statistical analysis due to missing phenotype data. Therefore, the effect of 
AXIN1 CNV in terms of the specific CNV Variant_4912 could not be statistically analysed. 
Nonetheless, two other CNV genotype groups were sufficiently represented in statistical 
analysis; CN gain (CN3) from the expected wild-type CN in the human diploid genome (CN2). 
In general, CNVs are thought to have quantitative effects, so CN loss or gain may equally 
affect a given trait. Moreover, evidence suggests the possibility of allelic heterogeneity at 
given genetic loci among different populations [142]. In view of this, even though the CN1 
genotype for AXIN1 CNV was not represented, the CN3 genotype could still be statistically  
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analysed. Therefore, this study tested the potential effect of the AXIN1 CNV in relation to 
BMD at three common skeletal locations of osteoporotic fracture (i.e. lumbar spine, total 
hip, and femoral neck) in a family-based population cohort study of Caucasian women from 
Australia  and  the  UK.  This  study  did  not  detect  any  statistically  significant  associations 
between AXIN1 CNV and BMD (g/cm
2) at the lumbar spine, total hip, or femoral neck, in the 
analysed subject cohort. Moreover, no associations were found between AXIN1 CNV and 
BMD after the BMD data were corrected for age (BMDZ) at the three skeletal locations in 
the cohort. Furthermore, no associations were found after testing the potential effect of 
covariates (i.e. age, age
2, height, weight, and BMI) on the relationship between AXIN1 CNV 
and BMD (g/cm
2) at the three skeletal locations in the cohort. Therefore, in this study of 
Caucasian women, the AXIN1 CNV genotype had no statistically significant effect on the 
BMD  phenotype.  However,  this  study  was  specifically  designed  to  target,  amplify,  and 
detect, Variant_4912, which constitutes a CN loss (CN1) from the expected wild-type (CN2). 
Therefore, the modified interpretation of AXIN1 CNV based on the two CNV genotypes that 
were  observed  (i.e.  CN2  and  CN3)  is  not  fully  comprehensive.  The  relatively  poor  CNV 
genotype coverage achieved in this study was potentially due to poor specificity of the 
TaqMan  Assays  in  terms  of  annealing  and  amplification,  but  further  research  would  be 
required to accurately elucidate this. 
In  summary,  this  study  successfully  genotyped  AXIN1  CNV  and  tested  for  its  potential 
association  with  BMD, but found  no  statistically  significant  association.  Previous  studies 
have indicated that the AXIN1 gene inhibits the Wnt signalling pathway [135; 136] and it has 
been demonstrated that Wnt signal transduction protects against phenotypes related to 
osteoporosis, such as low BMD [19]. Moreover, previous studies have implicated an AXIN1  
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SNP  with  BMD  [133].  Interestingly,  previous  studies  have  shown  that  AXIN1  negatively 
regulates the canonical Wnt signalling pathway by inhibiting the degradation of β-catenin 
[135; 136]. Moreover, β-catenin overexpression has been shown to reduce the promoter 
activity  of  RANKL  [139].  Therefore,  considering  that  RANKL  activates  osteoclasts  and 
promotes bone loss [18], a loss-of-function mutation related to AXIN1 CNV Variant_4912 
could potentially offer protection against phenotypes related to osteoporosis.  Therefore, 
AXIN1 CNV was anticipated to have a more significant effect on BMD than was found in this 
study, but whether data from this study would be replicated in a very large population study 
with sufficient statistical power, such as those used in recent GWAS meta-analyses (i.e. of 
the order of 80,000 subjects) remains to be elucidated. 
There have been no previous studies of the AXIN1 CNV Variant_4912 and hence its clinical 
relevance to BMD or other phenotypes related to the risk of osteoporosis remains to be 
elucidated. Therefore, it would be impossible to accurately validate or refute the findings 
without any corroborating evidence from previous studies. Nonetheless, there is evidence 
from  previous  studies  implicating  intron  2  of  the  AXIN1  gene  with  BMD.  Variant_4912 
encompasses the entirety of the AXIN1 gene, thereby implicating the transcriptional unit, 
which implicates gene expression, the fundamental level at which the genotype gives rise to 
the phenotype [67]. Therefore, despite the lack of statistically significant findings in this 
study, the AXIN1 CNV Variant_4912 still remains a promising candidate for involvement in 
BMD and the risk of osteoporosis. 
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Chapter 5: General Discussion and 
Conclusion 
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5.1 General Discussion 
Given what was already known about osteoporosis, gene expression, and CNV, the general 
purpose of this study was to investigate whether CNV of genomic regions, whose wild-type 
expression has previously been implicated with the regulation of bone, has an influence on 
the  regulation  of  the  surrogate  phenotype  for  osteoporosis,  BMD,  and  thus  whether  it 
influences the risk of developing the disease. 
Therefore, in an attempt to better elucidate the potential relationship between CNV and 
osteoporosis for further research, the main aim of this study was to examine the potential 
effect of two novel CNVs of the genes ESR1 and AXIN1, Variant_4512 and Variant_4912, 
respectively, in relation to BMD, in a population cohort study of Caucasian women. 
Furthermore, the specific aims, with which the main aim was addressed, were as follows; 
1) To attempt the accurate detection and quantitation of Variant_4512 and Variant_4912, 
respectively, in every subject of the study cohort, using relatively novel CNV genotyping 
techniques via qPCR combined with TaqMan chemistries, and the CN quantitation software, 
CopyCaller. 
2) To examine the potential effect of Variant_4512 and Variant_4912, respectively, in the 
study cohort, in relation to three different BMD phenotypes: 1) raw measurement (g/cm
2), 
2) age-adjusted Z-score, and 3) controlled for several covariates, at three common skeletal 
locations of osteoporotic fracture: 1) the lumbar spine, 2) total hip, and 3) femoral neck, 
using analyses of variance via the statistics software, SPSS.  
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5.1.1 CNV Detection and Quantitation 
Based on the experimental results obtained from the CNV genotyping component of this 
study, there are several interpretations which can be made for the analyses of ESR1 CNV 
and AXIN1 CNV. 
Firstly,  experimental  data  from  both  CNV  analyses  were  validated  as  reproducible  and 
reliable. No DNA amplification occurred in the NTC wells of every qPCR reaction plate run, 
thereby confirming that contamination of experimental reagents was successfully avoided. 
All  data  from  qPCR  and  CopyCaller  were  reasonably  consistent  between  replicates  with 
acceptable confidence levels. However, the VIC signal intensities on the CT scale tended to 
be more variable when compared with those of FAM. This may have been due to a higher 
degree of sensitivity and discrimination displayed by the TaqMan CN Reference Assays, but 
further research would be required to accurately validate this. The SPSS tests of normality 
(i.e. Shapiro-Wilk, Q-Q Plots and Box Plots) were largely inconsistent for both CNV analyses, 
with varying degrees of normality depending on the CNV status and BMD phenotype (i.e. 
data and location). Nonetheless, the majority of data tended slightly more towards normal 
distribution. Data lacking normality were most likely influenced by a lack of statistical power 
in this study due to an insufficient dataset from a moderately sized subject cohort, having 
many  subjects  that  could  not  be  statistically  analysed  due  to  missing  phenotype  data. 
Nonetheless, since the majority of data displayed normal distribution, it was reasonably 
assumed that association analyses could be performed using parametric tests via SPSS.  
Secondly,  the  genotype  distributions  observed  among  the  cohort  study  revealed  the 
presence  of  both  ESR1  CNV  and  AXIN1  CNV.  This  was  indicated  by  the  detection  of 
infrequent loss (CN1) and gain (CN3) from the expected human diploid wild-type CN for  
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both genes (CN2). Interestingly, the observed genotypes of CN loss for ESR1 (CN1) and CN 
gain for AXIN1 (CN3) were not expected, considering Variant_4512 constitutes a CN gain for 
ESR1  (CN3)  and  Variant_4912  constitutes  a  CN  loss  for  AXIN1  (CN1).  Whilst  the  exact 
reasoning  for  this  is  unclear,  there  are  several  possible  explanations,  including  poor 
specificity of the pre-designed TaqMan CN Assays in terms of annealing and amplification of 
the genomic region of interest, or inaccurate CN quantitation by CopyCaller from using only 
two technical replicates for each sample instead of the four that is recommended by ABI. 
Although experimental error and inconsistencies would appear to have the most obvious 
contribution towards the unexpected results, there might be some confounding feature 
about the CNVs that has not yet been elucidated. For example, the three observed CNV 
genotypes for both genes might be a result of allelic heterogeneity at their respective loci 
among different populations [111]. Further research would be required to comprehensively 
elucidate whether the observed CNV genotypes were in fact accurate, but due to limiting 
reagents and time constraints it was not feasible in this study. 
Another observation from the genotyping results in this study was that the frequencies of 
Variant_4512 and Variant_4912 were not the same as those reported by Wong et al in 2007 
in the discovery study for CNV detection. Instead, Variant_4512 and Variant_4912 were 
detected at frequencies of 0.99% and 0.2% in this study, which is significantly lower than the 
frequencies of 21% and 20% reported in the discovery study. The inconsistencies in CNV 
frequencies between this current study and the discovery study were most likely due to the 
differences in experimental conditions. The two subject cohorts were not representative of 
each  other  in  terms  of  the  distributions  of  subjects’  characteristics.  This  current  study 
consisted  exclusively  of  Caucasian  women,  while  the  discovery  study  consisted  of  both  
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women and men from a range of different ethnicities. This further highlights the possibility 
of allelic heterogeneity among different populations. The two methods of CNV detection 
were also different. This current study used qPCR combined with TaqMan Assay chemistries, 
while the discovery study used BAC array CGH analysis. Although experimental differences 
appear to be the most obvious reason as to why there was discrepancy in CNV frequencies 
between the two studies, the low frequencies observed in this study might ultimately signify 
that Variant_4512 and Variant_4912 are rare variants within the specific population cohort 
of  Caucasian  women  from  Australia  and  the  UK.  However,  further  research  would  be 
required to accurately elucidate this. Previous studies have suggested that rare variants may 
be as important as common variants in complex traits and diseases such as osteoporosis 
[50],  but  it  is  currently  difficult  to  reliably  detect  the  effects  of  rare variants  given  the 
constraints associated with sample size and sequencing [43]. 
Thirdly,  in  hindsight,  the  pre-designed  TaqMan  CN  Assay  used  to  detect  the  ESR1  CNV 
Variant_4512 appeared to have been poorly  selected  for  this  study.  It  was  intended  to 
target  the  middle  of  Variant_4512,  so  as  to  ensure  adequate  coverage  of  the  genomic 
region in terms of both annealing and amplification specificity. As a result, the CN Assay 
targeted  a  region  in  intron  2  of  the  ESR1  gene  and  subsequently  amplified  a  genomic 
sequence 88 bp in length [112]. However, a target location in intron 1 of ESR1 would have 
been more appropriate for this study, considering that previous studies have implicated 
genetic variations within intron 1 and the 5’ end of ESR1 with BMD [49; 98]. Moreover, a 
target location upstream of ESR1 and not overlapping any other coding regions may have 
also been appropriate, considering that previous studies have acknowledged the majority of 
known genes subject to CNV are not even located within the identified region of genetic  
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variation  [84],  and  that  osteoporosis  might  be  more  susceptible  to  genetic  variation 
affecting the CN of non-coding DNA sequences [89]. The pre-designed TaqMan CN Assay 
used to detect the AXIN1 CNV Variant_4912 had initially seemed appropriately selected for 
this study. Again, it was selected to target the middle of Variant_4912, so as to ensure 
adequate  coverage  of the  genomic  region  in  terms  of  both  annealing  and  amplification 
specificity. As a result, the CN Assay targeted a region in exon 3 of the AXIN1 gene and 
subsequently amplified a genomic sequence 110 bp in length [112]. However, this study 
detected Variant_4912 in only one subject, who could not be statistically analysed due to 
missing  phenotype  data.  However,  even  if  this  CNV  genotype  for  the  one  subject  was 
represented in statistical analysis, the statistical power would have been so low that there 
would have been minimal chance of yielding a significant result. Considering that previous 
studies  have  implicated  a  SNP  (rs9921222)  in  intron  2  of  AXIN1  with  BMD  [133], 
Variant_4912 was anticipated to have a more significant effect on BMD. Nonetheless, this 
study confirmed the presence of both ESR1 CNV and AXIN1 CNV in the analysed subject 
cohort, as indicated by the observation of three distinct CNV genotypes for each gene, 
representing  CN  loss  (CN1)  and  CN  gain  (CN3)  from  the  expected  wild-type  CN,  most 
frequent in the human diploid genome (CN2). 
5.1.2 CNV Association with BMD 
In summary, whilst the association analyses were successfully conducted and appropriately 
interpreted,  the  findings  in  this  study  illustrated  a  comprehensive  lack  of  association 
between BMD and CNV of both ESR1 and AXIN1, which was not consistent with what was 
initially hypothesised, based on what is already known about the two genes.  
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When considering the analysis of ESR1 CNV, Variant_4512 was anticipated to have a more 
significant effect on BMD than was found in this study. Previous studies have indicated that 
the  ESR1  gene  mediates  the  response  of  target  cells  to  oestrogen,  which  has  been 
demonstrated to protect against phenotypes related to osteoporosis, such as  low BMD. 
Moreover, previous studies have implicated several genetic variations of ESR1 with BMD. 
Nonetheless, results have been largely inconsistent between studies for statistical reasons, 
such as lack of power and study design [49], and more recently, it has been suggested that 
there could be allelic heterogeneity at the ESR1 locus among different populations [142]. 
Therefore, despite there being no evidence of association between ESR1 CNV and BMD in 
this  study,  given  different  experimental  conditions,  such  as  a  larger  sample  size  with  a 
related increase in statistical power, a statistically significant association may have been 
identified. Nonetheless, an interesting observation of this study was that the effect of ESR1 
CNV in relation to BMD (g/cm
2) at the femoral neck increased dramatically, and was noted 
as nominally significant, when controlled for several covariates (p = 0.052). It appears that 
this  near-significant  association  was  influenced  by  the  extremely  statistically  significant 
associations between BMD (g/cm
2) at the femoral neck, and age (p = < 0.001) and weight (p 
= 0.009). This finding was particularly meaningful for this study, considering what is already 
understood  about  both  osteoporosis  and  CNV.  Being  a  common  complex  disease, 
osteoporosis  involves  interactions  among  multiple  risk  factors  of  both  genetic  and 
environmental  sources  [42].  Moreover,  functional  CNVs  are  anticipated  to  encompass 
‘environmental sensor’ genes that are not critical for development, but mediate interaction 
with the environment [84]. Therefore, this could potentially explain how Variant_4512 could 
be  present  within  the  genome  of  an  otherwise  healthy  person  and  not  directly  cause 
osteoporosis, but instead contribute to an enhanced susceptibility (i.e. influence low BMD at  
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the femoral neck) given exposure to specific environmental factors (i.e. the stable factor of 
age and the modifiable factor of weight). Furthermore, Variant_4512 starts upstream of 
ESR1 in a genomic region of currently unknown expression and function, which may even 
turn out to be an ‘environmental sensor’ gene that influences BMD and osteoporosis risk. 
However,  these  are  hypothetical  interpretations  that  would  require  further  research  to 
accurately elucidate. 
When considering the analysis of AXIN1 CNV, the specific CNV Variant_4912 may not have 
been represented in statistical analysis, but the CNV genotype group CN3 was successfully 
analysed. However, this modified interpretation of AXIN1 CNV was anticipated to have a 
more significant effect on BMD than was found in this study. Previous studies have indicated 
that the AXIN1 gene inhibits the Wnt signalling pathway [135; 136] and that Wnt proteins 
protect  against  phenotypes  related  to  osteoporosis,  such  as  low  BMD  [19].  Moreover, 
previous studies have implicated a genetic variation of AXIN1 with BMD [133]. Repeating 
the experiments would have been beneficial towards validating the observed AXIN1 CNV 
genotypes, but due to limiting reagents and time constraints, it was unfeasible in this study. 
5.1.3 Recommendations for Further Study 
Due to a combination of numerous technical issues, limiting reagents, and time constraints, 
the general purpose of this study was not as comprehensively addressed as first intended. 
Nonetheless, this study cemented a preliminary foundation, based on important concepts 
and novel technologies, upon which future studies can build. Specifically, CNV assays for 
two key genes related to BMD were effectively established in the laboratory and the study 
cohort was successfully genotyped. Moreover, a protocol for the statistical approach for 
analysis of genotyped data from de novo CNV assays was also established. There are several  
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recommendations for further study of the potential effect of ESR1 CNV and AXIN1 CNV in 
relation  to  BMD  and the  risk  of  osteoporosis. Firstly,  it  would be  beneficial  to  select  a 
subject cohort of the largest possible size and to ensure that clinical phenotype data is 
recorded and stored appropriately for every subject, so as to ensure sufficient statistical 
power and to increase the chance of yielding a significant association [116]. Secondly, if the 
selected subject cohort is a family-based population, it would be beneficial to perform a 
family-based  population  analysis.  In  family-based  studies,  using  computer  software 
programs such as FBLAT and PLINK [142], genetic association of traits are assessed within 
families and hence the confounding effect of population heterogeneity can be eliminated 
[142]. Despite the fact that the GENOS (STH-S) cohort consists of twins and siblings and that 
BMD is a highly heritable trait, a family-based association analysis was deemed unnecessary 
for this current study, because none of the individuals with the ESR1 CNV Variant_4512 
were related. Lastly, it would be beneficial to also undertake cell-based expression studies 
to verify the normal activity of ESR1 and AXIN1 in regards to the regulation of bone, and the 
functional  effect  of  their  respective  CNVs.  Moreover,  the  identification  of  biochemical 
markers of phenotypes related to osteoporosis (i.e. excessive bone resorption) might just 
implicate  the  functional  consequence  of  CNV  with  the  pathogenesis  of  osteoporosis, 
thereby  validating  a  new  target  for  therapeutic  intervention  with  the  likelihood  of 
dramatically improving the quality of life for affected individuals. 
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5.2 Conclusion 
This  study  tested  the  hypothesis  that  CNV  is  associated  with  BMD  by  investigating  the 
potential effect of two novel CNVs of genes, ESR1 and  AXIN1, which have already been 
implicated  with  the  regulation  of  bone,  in  relation  to  BMD  measurements  at  multiple 
skeletal locations in a population study cohort of Caucasian women, between the ages of 18 
and 83, from Australia and the UK. 
Overall, this study effectively established CNV assays in the laboratory for two key genes 
related to BMD, and the study cohort was successfully genotyped. Moreover, a protocol for 
the statistical approach for analysis of genotyped data from the de novo CNV assays was 
also  successfully  established.  However,  this  study  failed  to  demonstrate  evidence  of  a 
statistically significant association between CNV and BMD and therefore the hypothesis is 
not supported. 
In specific summary, in a study of Caucasian women, both ESR1 CNV and AXIN1 CNV were 
accurately detected and quantitated using qPCR combined with TaqMan chemistries, and 
the CN quantitation software, CopyCaller. Moreover, the potential effect of both CNVs in 
relation  to  BMD  was  successfully  examined  using  analyses  of  variance  via  the  statistics 
package, SPSS. However, it can be concluded that both CNVs have no clinically relevant 
association  with  the  regulation  of  BMD  at  multiple  common  skeletal  locations  of 
osteoporotic fracture in the study cohort. Therefore, at this stage, both CNVs are unlikely to 
play a major role in the pathogenesis of osteoporosis. However, further research would be 
required to accurately validate this.  
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There have been no previous studies of the ESR1 CNV Variant_4512 or the AXIN1 CNV 
Variant_4912 and hence their clinical relevance to BMD or other phenotypes related to the 
risk  of  osteoporosis  remains  to  be  elucidated.  Therefore,  it  would  be  impossible  to 
accurately  validate  the  findings  of  this  study  without  any  corroborating  evidence  from 
previous studies. Nonetheless, there is evidence from previous studies implicating intron 1 
and the 5’ end of the ESR1 gene and intron 2 of the AXIN1 gene with BMD. Moreover, 
Variant_4512  and  Variant_4912  both  encompass  the  5’  end  of  their  respective  genes, 
thereby  implicating  the  promoter  sequence  and  regulatory  elements,  which  in  turn 
implicates  the  control of  gene  expression,  which  is  the  fundamental  level  at  which  the 
genotype gives rise to the phenotype. Therefore, despite the lack of statistically significant 
findings in this study, genomic CNVs of the genes ESR1 and AXIN1 still remain as promising 
candidates for involvement in BMD and the risk of osteoporosis. 
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Appendix 
1M TRIS 
1) 12.114g Tris 
2) 80mL ddH20 
3) Fill up to 100mL with ddH20 
4) Adjust pH level to 8 using HCl 
5) Autoclave to sterilise 
0.5M EDTA 
1) 18.612g EDTA 
2) 80mL ddH20 
3) Fill up to 100mL with ddH20 
4) Adjust pH level to 8 using NaOH 
5) Autoclave to sterilise 
TE BUFFER 
1) 1mL 1M TRIS, pH 8 (autoclaved)  
2) 0.2mL 0.5M EDTA, pH 8 (autoclaved) 
3) Fill up to 100mL with ddH20 
4) Autoclave to sterilise 